<!DOCTYPE html>
<html lang="en">
<head>
    <meta charset="utf-8">
    <meta http-equiv="X-UA-Compatible" content="IE=edge">
    <meta content="width=device-width, initial-scale=1, maximum-scale=1, user-scalable=no" name="viewport">
    <meta name="description" content="نظام معلومات الأدوية السعودي Saudi Drugs Information System">
    <meta name="author" content="Saudi Food & Drug Authority (SFDA)">
    <noscript><meta http-equiv="refresh" content="0; url=/noScript.html" /></noscript>
    <link rel="shortcut icon" href="/favicon.ico">
    <title>&#x646;&#x638;&#x627;&#x645; &#x645;&#x639;&#x644;&#x648;&#x645;&#x627;&#x62A; &#x627;&#x644;&#x623;&#x62F;&#x648;&#x64A;&#x629;</title>
    <link href="/fonts/roboto/roboto.css?v=53F8z0aw8DRnG9ou9x1tuKMPbNjRZWM-VBHl3B0s9-o" rel="stylesheet" />
    <link href="/fonts/material-icons/materialicons.css?v=8pEJ8MWsFzHRDLY0NI5rssf6T6vankxrJDPnnZxOGrg" rel="stylesheet" />
    <link href="/lib/bootstrap/dist/css/bootstrap-rtl.css?v=0env-Atj9mTPLILmJGwuDlLIOS_Akxxy4gnH1UUtrjU" rel="stylesheet" />
    <link href="/lib/bootstrap/dist/css/bootstrap-glyphicons.css?v=U5a39oen_WYzVAAexH5aoahbpqlKHcIzQrnXujf1yio" rel="stylesheet" />
    <link href="/lib/bootstrap-select/dist/css/bootstrap-select.css?v=DeY2lH0e0tmNnO9XZ-gGVOGk6_YoWlZ49y7CnD3ST00" rel="stylesheet" />
    <link href="/lib/toastr/toastr.css?v=kKePN_CyxTiMEgsSDu_7z21ru07YOZtR-0UV0JOkt5o" rel="stylesheet" />
    <link href="/lib/famfamfam-flags/dist/sprite/famfamfam-flags.css?v=JVJiF3s2_kk99xQHfYhfxo_-Dd52ZIruDMOILwPkqv0" rel="stylesheet" />
    <link href="/lib/font-awesome/css/font-awesome.css?v=YIHlqxkiJtENTMuzIHC9EfZaB5RniGr7kF7juUQJUuc" rel="stylesheet" />
    <link href="/lib/Waves/dist/waves.css?v=nd3hxjNg6DhkuFIz5IbxLK8Xw2ac0blsDQpF4pkJxUc" rel="stylesheet" />
    <link href="/lib/animate.css/animate.css?v=IT6GQizZpVcaM1_L_mIiNAYVvZErMgfwewf1GGWXG_I" rel="stylesheet" />
    <link href="/css/materialize.css?v=ey-J3xahkqficOYUHVX3jexmzvRFrge9bmux4CQr1DQ" rel="stylesheet" />
    <link href="/css/Publicstyle.css?v=xhOiVjq-54ODzSIeHXoascHsEJm_n_bIHqZatpxnYhg" rel="stylesheet">
    <link href="/css/Comman.css?v=bcS6_IRqBsBcY1mS_iriWWanrYR0Scdo1ffk8rQGXwQ" rel="stylesheet" />
    <link href="/css/themes/all-themes.css?v=eGSl5zNTWrXYfUx_EJW9ksC3CUTUUxvxmPiA3aQDtQo" rel="stylesheet" />
    <link href="/view-resources/Views/Shared/_Layout.css?v=BLxBuNISlF2O5EBHWdsX039NvnIHy-GtcqeI_MbyIc0" rel="stylesheet" />
    <link href="/lib/enjoyhint/enjoyhint.css?v=rSxIyBbiAvx_48ZcFxbn2DNPCCgEc0FXa2Vb72enxk4" rel="stylesheet" />
    <link href="/lib/dropzone/dropzone.css?v=IQDlHJdeYZ4gMH87EuB1yEG7ujA7DSEkV_SWfACk8Rg" rel="stylesheet" />

    <!-- View specific styles -->
    
    <script type="text/javascript" nonce="c7f26c8w">
        // This is used to get the application's root path from javascript. It's useful if you're running application in a virtual directory under IIS.
        var abp = abp || {};
        abp.appPath = '/';

    </script>
    <style>
        .popover .popover-title {
            text-align: right;
            font-weight: bold;
        }
        .popover .popover-content {
            text-align: right;
            font-size: 14px;
            font-family: 'Almarai', sans-serif;
            color: black;
        }
       
    </style>
</head>
<body>
    <!-- Page Loader -->
    <div class="page-loader-wrapper">
        <div class="loader">
            <div class="preloader">
                <div class="spinner-layer pl-blue">
                    <div class="circle-clipper left">
                        <div class="circle"></div>
                    </div>
                    <div class="circle-clipper right">
                        <div class="circle"></div>
                    </div>
                </div>
            </div>
            <p>&#x628;&#x631;&#x62C;&#x627;&#x621; &#x627;&#x644;&#x625;&#x646;&#x62A;&#x638;&#x627;&#x631; ...</p>
        </div>
    </div>
    <!-- #END# Page Loader -->
    <!-- Overlay For Sidebars -->
    <div class="overlay"></div>
    <!-- #END# Overlay For Sidebars -->
    <!-- Search Bar -->
    <!-- Top Bar -->
    <nav class="navbar navbar-inverse naav" style="margin-bottom: 0;">
        <div class="container-fluid">
            <div class="navbar-header">
                <button type="button" class="navbar-toggle" data-toggle="collapse" data-target="#myNavbar">
                    <span class="icon-bar"></span>
                    <span class="icon-bar"></span>
                    <span class="icon-bar"></span>
                </button>
            </div>
            <div class="collapse navbar-collapse rtl" id="navbar-collapse">
                <ul class="nav navbar-nav navbar-right">
                    <li><a href="/home/DrugSearch">&#x627;&#x644;&#x623;&#x62F;&#x648;&#x64A;&#x629;</a></li>
                        <li><a href="/Account/Login"><i class="fa fa-key"></i>&nbsp;&#x62A;&#x633;&#x62C;&#x64A;&#x644; &#x627;&#x644;&#x62F;&#x62E;&#x648;&#x644;</a></li>
                </ul>
                <ul class="nav navbar-nav navbar-left">
                    <li class="dropdown">
    <a href="javascript:void(0);" class="dropdown-toggle" data-toggle="dropdown" role="button">
        <i class="famfamfam-flags sa" title="&#x627;&#x644;&#x639;&#x631;&#x628;&#x64A;&#x629;"></i>
        <span>&#x627;&#x644;&#x639;&#x631;&#x628;&#x64A;&#x629;</span>
        <b class="caret"></b>
    </a>
    <ul class="dropdown-menu pull-right">
                <li><a href="/AbpLocalization/ChangeCulture?cultureName=en"><i class="famfamfam-flags gb"></i> English</a></li>

    </ul>
</li>

                </ul>
            </div>
        </div>
    </nav>
    <section id="mainContent" class="content">
        <nav class="navbar naav" style="margin-bottom: 0;">
            <div class="container-fluid">
                <ul class="nav navbar-nav">
                    <li>
                        <a class="text-center" href="/">
                            <img src="/images/logo_sdi.png" style="margin: auto;" width="250">
                        </a>
                    </li>
                </ul>
                <div class="navbar-header navbar-toggle2 ">
                    <button type="button" class="navbar-toggle navbar-toggle2" data-toggle="collapse"
                            data-target="#myNavbar2">
                        <span class="icon-bar icon-bar2 "></span>
                        <span class="icon-bar icon-bar2"></span>
                        <span class="icon-bar icon-bar2"></span>
                    </button>
                </div>
                <div class="collapse navbar-collapse " id="myNavbar2">
                    <ul class="nav navbar-nav">
                        <li>
                            <a href="#" class="text-right waves-effect" data-trigger="focus"
                               style="color: #4276a1;" data-container="body" data-toggle="popover" data-placement="bottom" title="" data-content="موقع الكترونى يمكن شركات ووكلاء الادويه من رفع النشرات الممارس الصحى ونشرة معلومات المريض وصورة عبوة الدواء المعتمدة من الهيئة العامة للعذاء والدواء بهدف بناء مرجع وطنى للادوية المسجلة يمكن الرجوع له من قبل الممارس الصحى والمريض كمصدر موثوق للمعلومات الدوائية"
                               data-original-title="&#x645;&#x646; &#x646;&#x62D;&#x646;">
                                &#x645;&#x646; &#x646;&#x62D;&#x646;
                            </a>
                        </li>
                        <li>
                            <a href="#" class="text-right waves-effect" data-trigger="focus"
                               style="color: #4276a1;" data-container="body" data-toggle="popover"
                               data-placement="bottom"
                               title=""
                               data-content="&#x627;&#x630;&#x627; &#x643;&#x627;&#x646; &#x644;&#x62F;&#x64A;&#x643;&#x645; &#x645;&#x644;&#x627;&#x62D;&#x638;&#x627;&#x62A; &#x627;&#x648; &#x627;&#x642;&#x62A;&#x631;&#x627;&#x62D;&#x627;&#x62A; &#x64A;&#x631;&#x62C;&#x649; &#x627;&#x644;&#x62A;&#x648;&#x627;&#x635;&#x644; &#x639;&#x644;&#x649;   SDI@SFDA.GOV.SA"
                               data-original-title="&#x62A;&#x648;&#x627;&#x635;&#x644; &#x645;&#x639;&#x646;&#x627;">
                                &#x62A;&#x648;&#x627;&#x635;&#x644; &#x645;&#x639;&#x646;&#x627;
                            </a>
                        </li>

                    </ul>
                </div>
            </div>
        </nav>
        

<div class="col-xs-12">
    <div class="row text-center">
        <a href="/" class="btn bg-blue btn-lg m-b-10 hover-white">&#x628;&#x62D;&#x62B; &#x62C;&#x62F;&#x64A;&#x62F;</a>
    </div>
</div>
<div class="jumbotron" style="margin-bottom: 0px; background-color: white !important;">
    <h3 class="text-center" style="color: #57aabf; ">Search Results</h3>
    <hr width="20%" style="border-top: 3px solid #54ae90;">

    <br>
    <table class="table s-row">
        <thead style="margin-bottom: 30px !important">
                <tr>
                    <th id="M" style="color:white;">
                        <a href="javascript:void(0)"
                           style="color: white;">&#x646;&#x634;&#x631;&#x629; &#x627;&#x644;&#x645;&#x645;&#x627;&#x631;&#x633; &#x627;&#x644;&#x635;&#x62D;&#x64A;</a>
                    </th>
                    <th id="A" style="color:white;" type='button'>
                        <a href="javascript:void(0)"
                           style="color: white;">&#x646;&#x634;&#x631;&#x629; &#x645;&#x639;&#x644;&#x648;&#x645;&#x627;&#x62A; &#x627;&#x644;&#x645;&#x631;&#x64A;&#x636; &#x628;&#x627;&#x644;&#x639;&#x631;&#x628;&#x64A;&#x629;</a>
                    </th>
                    <th id="E" style="color:white;" type='button'>
                        <a href="javascript:void(0)"
                           style="color: white;">&#x646;&#x634;&#x631;&#x629; &#x645;&#x639;&#x644;&#x648;&#x645;&#x627;&#x62A; &#x627;&#x644;&#x645;&#x631;&#x64A;&#x636; &#x628;&#x627;&#x644;&#x627;&#x646;&#x62C;&#x644;&#x64A;&#x632;&#x64A;&#x629;</a>
                    </th>
                    <th id="f" class="active-tab" type='button'>
                        <a href="javascript:void(0)" style="color: white;">&#x635;&#x648;&#x631; &#x627;&#x644;&#x62F;&#x648;&#x627;&#x621;</a>
                    </th>
                    <th id="D" style="color:white; background-color: #47a4ba;" type='button'>
                        <a href="javascript:void(0)"
                           style="color: white;">&#x628;&#x64A;&#x627;&#x646;&#x627;&#x62A; &#x627;&#x644;&#x62F;&#x648;&#x627;&#x621;</a>
                    </th>

                </tr>
        </thead>
    </table>
    <div id="D-div" class="box-data" style="display: block;">
        <div class="row">

<div class="modal-body rtl">
    <div class="tab-content">
        <div role="tabpanel" class="tab-pane m-r-60  animated fadeIn active" id="edit-user-details">
<div class="row clearfix">
                    <div class="col-lg-6 col-md-6 col-sm-6">
                        <div class="row clearfix">
                            <div class="col-sm-6">
                                <div class="form-group">
                                    <label class="form-label" for="RegisterNumber">&#x631;&#x642;&#x645; &#x627;&#x644;&#x62A;&#x633;&#x62C;&#x64A;&#x644;</label>
                                    <div class="form-line">
                                        0803233349
                                    </div>
                                </div>
                            </div>
                            <div class="col-sm-6">
                                <div class="form-group">
                                    <label class="form-label col-view" for="RegisterYear">&#x633;&#x646;&#x629; &#x627;&#x644;&#x62A;&#x633;&#x62C;&#x64A;&#x644;</label>
                                    <div class="form-line">
                                        2023
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                            <div class="col-sm-6">
                                <div class="form-group">
                                    <label class="form-label col-view" for="TradeName">&#x627;&#x644;&#x627;&#x633;&#x645; &#x627;&#x644;&#x62A;&#x62C;&#x627;&#x631;&#x64A;</label>
                                    <div class="form-line">
                                        Xolamol
                                    </div>
                                </div>
                            </div>
                            <div class="col-sm-6">
                                <div class="form-group">
                                    <label class="form-label col-view" for="ScientificName">&#x627;&#x644;&#x627;&#x633;&#x645; &#x627;&#x644;&#x639;&#x644;&#x645;&#x64A;</label>
                                    <div class="form-line">
                                        DORZOLAMIDE,TIMOLOL MALEATE
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                            <div class="col-sm-6">
                                <div class="form-group">
                                    <label class="form-label " for="Strength">&#x627;&#x644;&#x62A;&#x631;&#x643;&#x64A;&#x632;</label>
                                    <div class="form-line">
                                        20,5
                                    </div>
                                </div>
                            </div>
                            <div class="col-sm-6">
                                <div class="form-group">
                                    <label class="form-label" for="StrengthUnitName">&#x648;&#x62D;&#x62F;&#x629; &#x627;&#x644;&#x62A;&#x631;&#x643;&#x64A;&#x632;</label>
                                    <div class="form-line">
                                        mg/ml
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                            <div class="col-sm-6">
                                <div class="form-group">
                                    <label class="form-label" for="AdministrationRouteName">&#x637;&#x631;&#x64A;&#x642;&#x629; &#x627;&#x644;&#x625;&#x633;&#x62A;&#x639;&#x645;&#x627;&#x644;</label>
                                    <div class="form-line">
                                        Ocular use
                                    </div>
                                </div>
                            </div>
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="PharmaceuticalFormName">&#x627;&#x644;&#x634;&#x643;&#x644; &#x627;&#x644;&#x635;&#x64A;&#x62F;&#x644;&#x627;&#x646;&#x64A;</label>
                                    <div class="form-line">
                                        Eye drops, solution
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="Size">&#x627;&#x644;&#x62D;&#x62C;&#x645;</label>
                                    <div class="form-line">
                                        0
                                    </div>
                                </div>
                            </div>
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="SizeUnitName">&#x648;&#x62D;&#x62F;&#x629; &#x627;&#x644;&#x62D;&#x62C;&#x645;</label>
                                    <div class="form-line">
                                        
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="PackageSize">&#x62D;&#x62C;&#x645; &#x627;&#x644;&#x639;&#x628;&#x648;&#x629;</label>
                                    <div class="form-line">
                                        30
                                    </div>
                                </div>
                            </div>
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="PackageTypeName">&#x627;&#x646;&#x648;&#x627;&#x639; &#x627;&#x644;&#x639;&#x628;&#x648;&#x627;&#x62A;</label>
                                    <div class="form-line">
                                        Single Dose Container
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="LegalStatusName">&#x637;&#x631;&#x64A;&#x642;&#x629; &#x627;&#x644;&#x635;&#x631;&#x641;</label>
                                    <div class="form-line">
                                        Prescription
                                    </div>
                                </div>
                            </div>
                            <div class="col-sm-6">
                                <div class="form-group">
                                    <label class="form-label" for="ProductControlName">&#x62D;&#x627;&#x644;&#x629; &#x627;&#x644;&#x645;&#x631;&#x627;&#x642;&#x628;&#x629;</label>
                                    <div class="form-line">
                                        Uncontrolled
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="DrugTypeName">&#x646;&#x648;&#x639; &#x627;&#x644;&#x62F;&#x648;&#x627;&#x621;</label>
                                    <div class="form-line">
                                        Generic
                                    </div>
                                </div>
                            </div>
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="ShelfLife">&#x645;&#x62F;&#x629; &#x627;&#x644;&#x635;&#x644;&#x627;&#x62D;&#x64A;&#x629; &#x628;&#x627;&#x644;&#x623;&#x634;&#x647;&#x631;</label>
                                    <div class="form-line">
                                        24
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="StorageConditionsName">&#x634;&#x631;&#x648;&#x637; &#x627;&#x644;&#x62A;&#x62E;&#x632;&#x64A;&#x646;</label>
                                    <div class="form-line">
                                        do not store above 30°c
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="Price">&#x633;&#x639;&#x631; &#x627;&#x644;&#x62C;&#x645;&#x647;&#x648;&#x631; &#x628;&#x627;&#x644;&#x631;&#x64A;&#x627;&#x644;  ( &#x627;&#x644;&#x633;&#x639;&#x631; )</label>
                                    <div class="form-line">
                                        47.45
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                                <div class="col-sm-6 col-lg-6">
                                    <div class="form-group">
                                        <input type="hidden" id="Manufacture_NameEn" name="Manufacture.NameEn" value="Jamjoom Pharmaceuticals Factory Company" />
                                        <label class="form-label" for="Manufacture_NameEn">&#x627;&#x644;&#x645;&#x635;&#x646;&#x639;</label>
                                        <div class="form-line">
                                            Jamjoom Pharmaceuticals Factory Company
                                        </div>
                                    </div>
                                </div>
                                <div class="col-sm-6 col-lg-6">
                                    <div class="form-group">
                                        <input type="hidden" id="Agent" name="Agent" value="[Agent 394]" />
                                        <label class="form-label">&#x627;&#x644;&#x648;&#x643;&#x64A;&#x644;</label>
                                        <div class="form-line">
                                            JAMJOOM PHARMACEUTICALS CO. LTD.
                                        </div>
                                    </div>
                                </div>
                                <div class="col-sm-6 col-lg-6">
                                    <div class="form-group">
                                        <label class="form-label" for="Company_NameEn">&#x627;&#x644;&#x634;&#x631;&#x643;&#x629; &#x627;&#x644;&#x645;&#x633;&#x648;&#x642;&#x629;</label>
                                        <div class="form-line">
                                            Jamjoom Pharmaceuticals Factory Company
                                        </div>
                                    </div>
                                </div>
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="AtcCode1">&#x643;&#x648;&#x62F; &#x627;&#x644;&#x643;&#x64A;&#x645;&#x64A;&#x627;&#x621; &#x627;&#x644;&#x639;&#x644;&#x627;&#x62C;&#x64A;&#x629; &#x627;&#x644;&#x62A;&#x634;&#x631;&#x64A;&#x62D;&#x64A;&#x629; 1</label>
                                    <div class="form-line">
                                        S01EC03
                                    </div>
                                </div>
                            </div>
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="AtcCode2">&#x643;&#x648;&#x62F; &#x627;&#x644;&#x643;&#x64A;&#x645;&#x64A;&#x627;&#x621; &#x627;&#x644;&#x639;&#x644;&#x627;&#x62C;&#x64A;&#x629; &#x627;&#x644;&#x62A;&#x634;&#x631;&#x64A;&#x62D;&#x64A;&#x629; 2</label>
                                    <div class="form-line">
                                        S01ED01
                                    </div>
                                </div>
                            </div>
                        </div>
                    </div>
                </div>
        </div>
    </div>
</div>

        </div>
    </div>
    <div id="E-div" class="box-data">
<div class="p-20 text-center font-22">
            <div class="p-10 bg-light-blue  m-t-20 m-b-20 ltr">
                <i class="fa fa-info-circle"></i>&nbsp;
                <span style="font-size: large; background-color: rgb(245,245,245); color: rgb(51,51,51); "> SFDA PIL</span>
                <span style="font-size:small;">  (Patient Information Leaflet (PIL) are under review by Saudi Food and Drug Authority)</span>

            </div>
</div>


<div class="clearfix ltr">
    <div class="col-lg-12 col-md-12 col-sm-12 col-xs-12">
        <div class="clearfix">
            <label class="h2" for="InventedNameEn">1. What this product is and what it is used for</label>
        </div>
        <div class="form-group">
            <br />
            <div class="m-l-60">
                <p>XolamolTM U.D contains two medicines: dorzolamide and timolol.<br />&bull; Dorzolamide belongs to a group of medicines called &quot;carbonic anhydrase inhibitors&quot;.<br />&bull; Timolol belongs to a group of medicines called &quot;beta blockers&quot;.<br />These medicines lower pressure in the eye in different ways.<br />XolamolTM U.D are prescribed to lower raised pressure within the eye in the treatment<br />of glaucoma when beta-blocker eye drops used alone are not adequate.</p>
            </div>
        </div>
    </div>
    <div class="col-lg-12 col-md-12 col-sm-6 col-xs-12">
        <div class="form-group clearfix">
            <label style="float: left" class="h2" for="PrecautionsEn">2. What you need to know before you use this product</label>
        </div>
        <div class="form-group">
            <br />
            <div class="m-l-60">
                <p>Do not use XolamolTM U.D if you<br />&bull; are allergic to dorzolamide or timolol, beta blockers or any of the other ingredients of<br />this medicine (listed in section 6).<br />&bull; have now or have had in the past respiratory problems such as asthma, severe chronic<br />obstructive bronchitis (severe lung disease which may cause wheeziness, difficulty in<br />breathing and/or long-standing cough).<br />&bull; have severe kidney problems, or a prior history of kidney stones.<br />&bull; have a disturbance in the pH (acid /alkali balance) of your blood.<br />&bull; have certain heart problems,including certain heart rhythm disturbances producing an<br />abnormally slow heart rate or severe heart failure.<br />If you think any of these apply to you, do not use XolamolTM U.D until you have<br />consulted your doctor.<br />Take special care with XolamolTM U.D<br />Talk to your doctor before using Xolamol&trade; U.D<br />Tell your doctor about any medical or eye problems you have now or have had in the<br />past,<br />&bull; coronary heart disease (symptoms can include chest pain or tightness, breathlessness<br />or choking), heart failure, low blood pressure.<br />&bull; disturbances of heart rate such as slow heart beat.<br />&bull; breathing problems, asthma or chronic obstructive pulmonary disease.<br />&bull; poor blood circulation disease (such as Raynaud&#39;s disease or Raynaud&#39;s syndrome)<br />&bull; diabetes as timolol may mask signs and symptoms of low blood sugar.<br />&bull; over activity of the thyroid gland as timolol may mask signs and symptoms.<br />Tell your doctor before you have an operation that you are using XolamolTM U.D as<br />timolol may change effects of some medicines used during anaesthesia.<br />Also tell your doctor about any allergies or anaphylactic reactions.<br />&bull; if you have muscle weakness or have been diagnosed as having myasthenia gravis.<br />&bull; any allergies to a medicine you have taken.<br />If you develop conjunctivitis (redness and irritation of the eyes), swelling of the eye or<br />eyelids, skin rash or itching in and around the eye contact your doctor immediately.<br />Such symptoms may be due to an allergic reaction or may be a side-effect of<br />XolamolTM U.D (See &lsquo;Possible Side Effects&rsquo;).<br />Tell your doctor if you develop an eye infection, receive an eye injury, have eye<br />surgery, or develop a reaction including new or worsening symptoms.<br />When XolamolTM U.D is instilled into the eye it may affect the entire body.<br />XolamolTM U.D has not been studied in patients wearing contact lenses. If you wear<br />soft contact lenses, you should consult your doctor before using this medicine.<br />Use in children<br />There is limited experience with (Dorzolamide/Timolol) in infants and children.<br />Use in elderly<br />In studies with (Dorzolamide/Timolol), the effects of (Dorzolamide/Timolol) were<br />similar in both elderly and younger patients.<br />Use in patients with liver impairment<br />Tell your doctor about any liver problems you now have or have suffered from in the<br />past.</p><p>Using other medicines<br />XolamolTM U.D can affect or be affected by other medicines you are using, including<br />other eye drops for the treatment of glaucoma. Tell your doctor or pharmacist if you<br />are taking, have recently taken or might take any other medicines, including medicines<br />obtained without a prescription. This is particularly important if you are:<br />&bull; taking antihypertensive medicines which are used to lower high blood pressure or<br />medicines to treat heart disease (such as calcium channel blockers, beta-blockers or<br />digoxin).<br />&bull; taking medicines to treat a disturbed or irregular heartbeat (such as calcium channel<br />blockers, beta-blockers or digoxin).<br />&bull; using another eye drop that contains a &szlig;-blocker.<br />&bull; taking another carbonic anhydrase inhibitor such as acetazolamide.<br />&bull; taking monoamine oxidase inhibitors (MAOIs).<br />&bull; taking a parasympathomimetic medicine which may have been prescribed to help<br />you pass urine. Parasympathomimetics are also a particular type of medicine which are<br />sometimes used to help restore normal movements through the bowel.<br />&bull; taking narcotics such as morphine used to treat moderate to severe pain.<br />&bull; taking medicines to treat diabetes.<br />&bull; taking antidepressants known as fluoxetine and paroxetine.<br />&bull; taking a sulfa medicine.<br />&bull; taking quinidine (used to treat heart conditions and some types of malaria).<br />Pregnancy and breast-feeding<br />If you are pregnant or breast-feeding, think you may be pregnant or are planning to<br />have a baby, ask your doctor or pharmacist for advice before taking this medicine.<br />Do not use XolamolTM U.D if you are pregnant unless your doctor considers it<br />necessary.<br />Do not use XolamolTM U.D if you are breast-feeding. Timolol may get into your milk.<br />Driving and using machines<br />No studies on the effects on the ability to drive or use machines have been performed.<br />There are side effects associated with XolamolTM U.D such as blurred vision which<br />may affect your ability to drive and/or operate machinery. Do not drive or operate<br />machinery until you feel well or your vision is clear.</p>
            </div>
        </div>
    </div>
    <div class="col-lg-12 col-md-12 col-sm-6 col-xs-12">
        <div class="clearfix">
            <label class="h2" for="AdministrationRoutesEn">3. How to use this product.</label>
        </div>
        <div class="form-group">
            <br />
            <div class="m-l-60">
                <p>Always use XolamolTM U.D exactly as your doctor has told you. You should check<br />with your doctor or pharmacist if you are not sure.<br />The appropriate dosage and duration of treatment will be established by your doctor.<br />The recommended dose is one drop in the affected eye(s) in the morning and in the<br />evening.<br />If you use XolamolTM U.D with another eye drop, the drops should be instilled at least<br />10 minutes apart.<br />Do not change the dosage of the drug without consulting your doctor.<br />If you have difficulty administering your eye drops, seek the assistance of a family<br />member or carer.<br />Do not allow the single dose container to touch the eye or areas around the eye. It<br />could cause injury to your eye. It may also become contaminated with bacteria that can<br />cause eye infections leading to serious damage of the eye, even loss of vision. To<br />avoid possible contamination of the single dose container, wash your hands before<br />using this medicine and keep the tip of the single dose container away from contact<br />with any surface.<br />Instructions for use<br />&bull; First wash your hands.<br />&bull; Remove the tip of the unit.<br />&bull; Tilt your head back a little and pull the lower lid of your eye downwards to form a<br />pocket.<br />&bull; Hold the single-use unit upside down near to your eye.<br />&bull; Try not to touch your eye as you do this.<br />&bull; Apply enough pressure to release one drop into your eye.<br />&bull; Close your eye for a minute or two, and press gently on the side of your nose where<br />the corner of your eye meets your nose. This helps to stop the drop from draining away<br />and keeps it in your eye.<br />&bull; Repeat the process in your other eye.<br />&bull; After using the single-use unit throw it away.<br />If you use more Xolamol&trade; U.D than you should<br />If you put too many drops in your eye or swallow any of the contents of the container,<br />among other effects, you may become light-headed, have difficulty breathing, or feel<br />that your heart rate has slowed. Contact your doctor immediately.</p><p>If you forget to use XolamolTM U.D<br />It is important to use XolamolTM U.D as prescribed by your doctor.<br />If you miss a dose, use it as soon as possible. However,if it is almost time for the next<br />dose, skip the missed dose and go back to your regular dosing schedule.<br />Do not use a double dose to make up for forgotten individual doses.<br />If you stop taking XolamolTM U.D<br />If you want to stop using this medicine talk to your doctor first.<br />If you have any further questions on the use of this product, ask your doctor or<br />pharmacist.</p>
            </div>
        </div>
    </div>
    <div class="col-lg-12 col-md-12 col-sm-6 col-xs-12">
        <div class="clearfix">
            <label class="h2" for="SideEffectsEn">4. Possible side effects</label>
        </div>
        <div class="form-group">
            <br />
            <div class="m-l-60">
                <p>Like all medicines, this medicine can cause side effects, although not every body gets<br />them.<br />You can usually carry on taking the drops, unless the effects are serious. If you&#39;re<br />worried, talk to a doctor or pharmacist.<br />Do not stop using XolamolTM U.D without speaking to your doctor.<br />&bull; Generalized allergic reactions including swelling beneath the skin that can occur in<br />areas such as the face and limbs, and can obstruct the airway which may cause<br />difficulty swallowing or breathing, hives or itchy rash, localized and generalized rash,<br />itchiness, severe sudden life-threatening allergic reaction.<br />The frequency of possible side effects listed below is defined using the following<br />convention:<br />Very common (affects more than 1 user in 10)<br />Common (affects 1 to 10 users in 100)<br />Uncommon (affects 1 to 10 users in 1,000)<br />Rare (affects 1 to 10 users in 10,000)<br />Not known (frequency cannot be estimated from the available data)<br />The following side effects have been reported with (dorzolamide / timolol) or one of its<br />components either during clinical trials or during post-marketing experience:<br />Very Common<br />Burning and stinging of the eyes, taste perversion.<br />Common<br />Redness in and around the eye(s), watering or itching of the eye(s), and effects on the<br />surface of the eye(s), swelling and/or irritation in and around the eye(s), feeling of<br />having something in the eye (corneal erosion), decreased corneal sensitivity (not<br />realising of getting something in the eye and not feeling pain), eye pain, dry eyes,<br />blurred vision, headache, sinusitis (feeling of tension or fullness in the nose), feeling<br />sick, also called nausea, weakness/tiredness and fatigue.<br />Uncommon<br />Dizziness, depression, inflammation of the iris, blurred vision (due to withdrawal of<br />miotic therapy in some cases), slow heartbeat, fainting, difficulty breathing (dyspnoea),<br />indigestion, and kidney stones.<br />Rare<br />Systemic lupus erythematosus (an immune disease which may cause an inflammation<br />of internal organs), tingling or numbness of the hands or feet, insomnia, nightmares,<br />memory loss, an increase in signs and symptoms of myasthenia gravis (muscle<br />disorder), decreased sex drive, stroke, temporary short sightedness which may resolve<br />when treatment is stopped, detachment of the layer below the retina that contains blood<br />vessels following from filtration surgery which may cause visual disturbances,<br />drooping of the eyelids (making the eye stay half closed), double vision, eyelid<br />crusting, swelling of the cornea (with symptoms of visual disturbances), low pressure<br />in the eye, ringing noises in your ear, low blood pressure, changes in the rhythm or<br />speed of the heartbeat, congestive heart failure (heart disease with shortness of breath<br />and swelling of feet and legs due to fluid build up), oedema (fluid build up), cerebral<br />ischaemia (reduced blood supply to the brain), chest pain, palpitations (a quicker<br />and/or irregular heartbeat), heart attack, Raynaud&#39;s phenomenon, swelling or coldness<br />of your hands and feet and reduced circulation in your arms and legs, leg cramps<br />and/or leg pain when walking (claudication), shortness of breath, respiratory failure,<br />rhinitis, nose bleed, constriction of the airways in the lungs, cough, throat irritation, dry<br />mouth, diarrhoea, contact dermatitis, hair loss, skin rash with white silvery coloured<br />appearance (psoriasiform rash), Peyronie&rsquo;s disease (which may cause a curvature of the<br />penis), allergic type reactions such as rash, hives, itching, in rare cases possible<br />swelling of the lips, eyes and mouth, wheezing, or severe skin reactions (Stevens<br />Johnsons syndrome, toxic epidermal necrolysis).<br />Like other medicines applied into your eyes, timolol is absorbed into the blood. This<br />may cause similar side effects as seen with oral beta-blocking agents. Incidence of side<br />effects after topical ophthalmic administration is lower than when medicines are, for<br />example, taken by mouth or injected. Listed additional side effects include reactions<br />seen within the class of beta-blockers when used for treating eye conditions.<br />Frequency unknown:<br />Low blood glucose levels, heart failure, stomach pain and vomiting, muscle pain not<br />caused by exercise, sexual dysfunction.<br />If any of the side effects gets serious, or if you notice any side effects not listed in this<br />leaflet. please tell your doctor or pharmacist, particularly if you experience any<br />changes/visual disturbance when using XolamolTM U.D after eye surgery.</p>
            </div>
        </div>
    </div>
    <div class="col-lg-12 col-md-12 col-sm-6 col-xs-12">
        <div class="clearfix">
            <label class="h2" for="StorageConditionsEn">5. How to store this product</label>
        </div>
        <div class="form-group">
            <br />
            <div class="m-l-60">
                <p>&bull; Keep out of the reach and sight of children.<br />&bull; Do not store above 30 &ordm;C.<br />&bull; Do not freeze. Store in pouches in order to protect from light.<br />&bull; Do not use more than 30 days after opening the Alu-Alu pouch.<br />&bull; Use eye drops immediately after opening the container.<br />&bull; Discard the opened container with any remaining contents immediately after use.<br />&bull; Do not use Xolamol&trade; U.D after the expiry date which is stated on the carton after<br />&lsquo;Exp&rsquo;.<br />&bull; Discard the opened single dose container with any remaining solution immediately<br />after first use.<br />&bull; Medicines should not be disposed of via waste water or household waste. Ask your<br />pharmacist how to dispose of medicines no longer required. This will help protect the<br />environment.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-12">
        <label style="float: left">6. Further information</label>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label class="h2" for="IngredientsEn">a. What this product contains</label>
        </div>
        <div class="form-group">
            <br />
            <div class="m-l-60">
                <p>&bull; The active substances are dorzolamide and timolol.<br />Each ml contains:<br />Dorzolamide Hydrochloride 22.25 mg (equivalent to Dorzolamide 20 mg) and<br />Timolol Maleate 6.83mg (equivalent to Timolol 5mg).<br />&bull; The other ingredients are hydroxyethyl cellulose, mannitol, sodium citrate,<br />sodium hydroxide and/or hydrochloric acid (for pH adjustment) and water for<br />injection.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label class="h2" for="ShapeAndContentsEn">b. What this product looks like and contents of the pack</label>
        </div>
        <div class="form-group">
            <br />
            <div class="m-l-60">
                • XolamolTM U.D is a clear colorless solution.
• XolamolTM U.D is supplied as a 30 single use units, preservative-free, air tight LDPE
units arranged in 6 Alu-Alu covered pouches each contains 5 single use units.
Each single use unit has 0.2 ml of eye drops inside.
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label class="h2" for="ManufacturingAndMarketingEn">c. Marketing Authorization Holder and Manufacturer</label>
        </div>
        <div class="form-group">
            <br />
            <div class="m-l-60">
                <p>Jamjoom Pharmaceuticals Factory Co.,<br />Jeddah, Makkah Region, Saudi Arabia.<br />Tel: +966-12-6081111 Fax: +966-12-6081222<br />Website: www.jamjoompharma.com<br />Please report adverse drug events to:<br />&bull; Saudi Arabia:<br />The National Pharmacovigilance Centre (NPC):<br />o Fax: +966-11-205-7662<br />o SFDA Call Center: 19999<br />o E-mail: npc.drug@sfda.gov.sa<br />o Website: https://ade.sfda.gov.sa<br />&bull; Other GCC States:<br />&minus; Please contact the relevant competent authority.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label class="h2" for="RevisionNoteEn">d. This leaflet was last revised in {MM/YYYY}</label>
        </div>
        <div class="form-group">
            <br />
            <div class="m-l-60">
                This leaflet was last reviewed at 11/2024; Version number 02.
            </div>
        </div>
    </div>
</div>    </div>
    <div id="A-div" class="box-data">
<div class="p-20 text-center font-22">
            <div class="p-10 bg-light-blue  m-t-20 m-b-20 ltr">
                <i class="fa fa-info-circle"></i>&nbsp;
                <span style="font-size: large; background-color: rgb(245,245,245); color: rgb(51,51,51); "> نشرة الدواء تحت مراجعة الهيئة العامة للغذاء والدواء</span>
                <span style="font-size:small;">  (اقرأ هذه النشرة بعناية قبل البدء في استخدام هذا المنتج لأنه يحتوي على معلومات مهمة لك)</span>
            </div>
    <div class="p-10 bg-light-blue font-15 m-t-20 m-b-20 ltr">

    </div>

</div>
<div class="clearfix rtl">
    <div class="col-xs-12">
        <div class="form-group clearfix">
            <label class="h2" for="InventedNameAr">1. ما ھو هذا المستحضر وماھي دواعي استعماله</label>
        </div>
        <div class="form-group clearfix" style="float: right">
            <br />
            <p dir="ltr">على عقارین: دورزولامید و تیمولول. U.D &trade; یحتوي زولامول<br />&bull; تنتمي مادة الدُّورزولامید إلى مجموعة من الأدویة تسمى &quot;مثبِّطات إنزیم أنھیدراز الكَربونیك&quot; .<br />&bull; تنتمي مادة التیمولول إلى مجموعة من الأدویة تسمى &quot;حاصرات بیتا&quot;.<br />ھذه الأدویة تقلل ضغط العین بطرق مختلفة.<br />لعلاج ضغط العین المرتفع في علاج حالات الجلوكوما عندما تكون القطرات U.D &trade; &bull; یوصف زولامول<br />المحتویة على حاصرات بیتا وحدھا غیر كافیة.<br />.U.D &trade; ۲- قبل أن تستخدم</p>
        </div>
    </div>
    <div class="col-xs-12">
        <div class="form-group clearfix">
            <label class="h2" for="PrecautionsAr">2. ما الذي يجب عليك معرفته قبل استعمال هذا المستحضر</label>
        </div>
        <div class="m-r-60">
            <p>.U.D &trade; ۲- قبل أن تستخدم زولامول<br />إذا كنت: U.D &trade; لا تستخدم زولامول<br />&bull; إذا كنت تعاني من فرط الحساسیة للدُّورزولامید أو التیمولول أو حاصرات البیتا أو أي من مكونات ھذا<br />.( الدواء الأخرى (مذكورة في القسم ٦<br />&bull; تعاني حالیاً أو عانیت فیما سبق من مشاكل في الجھاز التنفسي مثل نوبات الربو، حالات حادة من مرض<br />الإنسداد الرئوي المزمن (وھو مرض رئوي یؤدي إلى أزیز، صعوبة في التنفس، و/أو سعال لمدة طویلة).<br />&bull; لدیك مشاكل حادة في الكلى، أو تاریخ سابق من حصوات الكلى.<br />&bull; لدیك إضطرابات في درجة حموضة الدم ( توازن الحمض/ القلوي).<br />&bull; لدیك مشاكل معینة في القلب، تشمل اضطرابات معینة في إیقاع نبضات القلب والتي ینتج عنھا بطء غیر<br />طبیعي في معدل ضربات القلب أو فشل حاد في القلب.<br />حتى تستشیر طبیبك. U.D &trade; إذا كنت تعتقد أن أي مما سبق ینطبق علیك فلا تستخدم زولامول<br />:U.D &trade; إتخذ إحتیاطات خاصة عند إستخدام زولامول<br />U.D &trade; تحدث مع طبیبك قبل استخدام زولامول<br />أخبر طبیبك إذا كنت تعاني حالیاً أو فیما سبق من مشاكل طبیة أو مشاكل في العین ،<br />&bull; أمراض القَلْبِ التَّاجِیُّة (یمكن أن تشمل الأعراض ألم أو ضیق في الصدر، ضیق التنفس أو الاختناق)<br />وفشل في القلب وانخفاض ضغط الدم.<br />&bull; إضطرابات في معدل نبضات القلب مثل البطء في ضربات القلب.<br />&bull; مشاكل في التنفس مثل نوبات الربو أو مرض الانسداد الرئوي المزمن.<br />&bull; أمراض ضعف الدورة الدمویة (مثل مرض رینود أو متلازمة رینود).<br />&bull; مرض السكر حیث قد یخفي التیمولول أعراض و علامات انخفاض مستوى السكر في الدم.<br />&bull; زیادة نشاط في الغدة الدرقیة یمكن أن یخفي تیمولول الأعراض و العلامات.<br />حیث أن تیمولول قد یغیر تأثیر بعض الأدویة U.D &trade; &bull; أخبر طبیبك قبل الجراحة انك تستخدم زولامول<br />المستخدمة أثناء التخدیر.<br />أخبر طبیبك أیضاً عن أي حساسیة أو تفاعلات تحسسیة.<br />&bull; إذا كان لدیك ضعف في العضلات أو قد تم تشخیصك بوجود مرض الوَھَنٌ العَضَلِيٌّ الوَبیل.<br />&bull; أي نوع من أنواع الحساسیة تجاه دواء معین كنت قد تناولتھ. إذا كنت تعاني من التھاب في الملتحمة<br />(إحمرار وتھیج في العینین)، وتورم في العین أو الجفون، طفح جلدي أو حكة في وحول العین، اتصل<br />بطبیبك على الفور.<br />&bull; قد تكون مثل ھذه الأعراض بسبب رد الفعل التحسسي أو قد تكون إحدى الآثار الجانبیة<br />انظر&quot; التأثیرات الجانبیة المحتملة). ) U.D &trade; لزولامول<br />&bull; أخبر طبیبك إذا أُصِبت بأي عدوى أو جرح في العین، تخضع لجراحة بالعین، لدیك أي تفاعلات بما في<br />ذلك أعراض جدیدة أو تفاقم في الأعراض.<br />في العین قد تؤثر على الجسم بأكملھ. U.D &trade; عندما وضع زولامول<br />في المرضى الذین یرتدون العدسات اللاصقة. إذا كنت ترتدي العدسات U.D &trade; لم یدرس زولامول<br />اللاصقة اللینة، یجب استشارة الطبیب قبل استخدام ھذا الدواء.<br />الإستخدام مع الأطفال:<br />ھناك خبرة محدودة مع إستخدام (دورزولامید والتیمولول) في الرضع والأطفال.<br />الإستخدام مع كبار السن:<br />في الدراسات التي أُجریت على (دورزولامید والتیمولول) كان المفعول مماثلاً في كل من كبار السن<br />والأشخاص من الفئة العمریة الأقل.<br />الإستخدام مع المرضى الذین یعانون من قصور الكبد<br />أخبر طبیبك عن أي مشاكل لدیك في الكبد الآن أو عانیت منھا في الماضي.<br />إستخدام أدویة أخرى:<br />أو یتأثر بالأدویة الأخرى التي تستخدمھا لعلاج الجلوكوما. یرجى إخبار U.D &trade; یمكن أن یؤثر زولامول<br />طبیبك أو الصیدلي إذا كنت تتناول أو تناولت مؤخراً أو ربما تتناول أي أدویة أخرى، بما في ذلك الأدویة<br />التي یتم الحصول علیھا بدون وصفة طبیة وخاصة إذا كنت :<br />&bull; تتناول أدویة لعلاج ضغط الدم المرتفع أو أمراض القلب (مثل حاصرات قنوات الكالسیوم وحاصرات بیتا<br />أو الدیجوكسین).<br />&bull; تتناول أدویة لعلاج إضطرابات أو عدم انتظام نبضات القلب (مثل حاصرات قنوات الكالسیوم<br />وحاصرات بیتا أو الدیجوكسین).<br />&bull; تستخدم أنواع أخرى من قطرات العین تحتوي على حاصرات بیتا.<br />&bull; تتناول أدویة أخرى تحتوي على مثبِّطات إنزیم أنھیدراز الكَربونیك.<br />.(MAOIs) &bull; تتناول أحد مثبِّطُات أكسیدازِ أُحاديِّ الأمین<br />&bull; تتناول إحدى مُنبھات العصب نظیر الودي والتي یمكن أن توصف لك للمساعدة على التبول. و تُعد<br />مُنبھات العصب نظیر الودي نوعا خاصاً من الأدویة التي تستخدم في بعض الأحیان للمساعدة على استعادة<br />الحركات الطبیعیة في الأمعاء.<br />&bull; تتناول المواد المخدرة مثل المورفین والتي تستخدم لتسكین الألم المتوسط إلى الحاد.<br />&bull; تتناول أدویة لعلاج مرض السكر.<br />&bull; تتناول مضادات الاكتئاب المعروفة باسم فلوكسیتین و باروكسیتین.<br />&bull; تتناول دواء السلفا.<br />&bull; تتناول الكینیدین (یستخدم لعلاج حالات القلب وبعض أنواع المالاریا).<br />الحمل والرضاعة الطبیعیة:<br />إستشیري طبیبك أو الصیدلي قبل إستخدام ھذا الدواء. إذا كنت حاملا أو تقومین بالرضاعة الطبیعیة،<br />تعتقدین بأنك قد تكوني حاملا أو تخططین لأن تصبحي حاملا.<br />خلال فترة الحمل ما لم یوصي الطبیب بضرورة ذلك. U.D &trade; لا ینبغي إستخدام زولامول<br />أثناء فترة الرضاعة الطبیعیة لأن التیمولول یمكن أن یمر من خلال U.D &trade; لا ینبغي إستخدام زولامول<br />لبن الأم.<br />القیادة و تشغیل الآلات:<br />آثاراً جانبیة مثل عدم وضوح الرؤیة عند بعض المرضى. لا تقم U.D &trade; قد یسبب إستخدام زولامول<br />بالقیادة أو إستخدام أي أدوات أو آلات حتى تزول تلك الأعراض.<br />لا یوجد دراسات عن الآثار على القدرة القیادة أو إستخدام الآلات. ھناك آثار جانبیة مرتبطة<br />قد مثل عدم وضوح الرؤیة التي قد تؤثر على قدرتك على القیادة و / أو تشغیل الآلات. U.D &trade; بزولامول<br />لا تقم بالقیادة أو تشغیل الآلات حتى تشعر بالتحسن أو وضوح الرؤیة.<br />&nbsp;</p>
        </div>
    </div>
    <div class="col-xs-12">
        <div class="clearfix">
            https://localhost:44358/Dashboard
            <label class="h2" for="AdministrationRoutesAr">3. ماھي طريقة استعمال هذا المستحضر</label>
        </div>
        <div class="m-r-60">
            <p>۳. كیفیة إستخدام زولامول<br />تماماً كما وصفھا لك الطبیب. إذا كنت غیر متأكداً فینبغي علیك الرجوع U.D &trade; إستخدم دائما زولامول<br />إلى طبیبك أو الصیدلي.<br />سیتم تحدید الجرعة ومدة العلاج المناسبة من قبل الطبیب.<br />الجرعة الموصى بھا ھي نقطة واحدة في العین المصابة أو كلتا العینین المصابتین في الصباح وفي<br />المساء.<br />مع أي قطرات أخرى للعین، یجب وضع القطرات بفارق لا یقل عن U.D &trade; إذا كنت تستخدم زولامول<br />۱۰ دقائق عن بعضھا البعض.<br />لا تقم بتغییر جرعة الدواء دون استشارة الطبیب.<br />إذا كان لدیك صعوبة في إستخدام قطرات العین، للحصول على المساعدة من أحد أفراد العائلة أو مقدم<br />الرعایة.<br />لا تسمح لحاویة الجرعة الأحادیة بالمس العین أو المناطق حول العین. فیمكن أن تتسبب في إصابة العین.<br />كما قد تصبح ملوثة بالبكتیریا التي یمكن أن تسبب التھابات العین مما یؤدي إلى أضرار خطیرة للعین،<br />حتى فقدان الرؤیة. لتجنب التلوث المحتمل للجرعة الأحادیة، أغسل یدیك قبل استخدام ھذا الدواء، واحفظ<br />طرف الجرعة الأحادیة بعیدا عن التلامس مع أي سطح.<br />تعلیمات للإستخدام<br />&bull; اغسل یدیك أولا.<br />&bull; إخلع رأس الوحدة.<br />&bull; سحب الجفن السفلي إلى أسفل برفق، ومن ثم ضع بعنایة قطرة واحدة داخل الجفن السفلي، في الزاویة<br />الأقرب إلى الأنف.<br />&bull; حرر الجفن السفلي، وأغلق وافتح العین عدة مرات للتأكد من تغطیة العین عن طریق السائل.<br />في كلتا العینین قم باتباع نفس الخطوات للعین الأخرى. U.D &trade; &bull; إذا كنت تستخدم زولامول<br />&bull; تخلص من الوحدة الأحادیة الجرعة بعد الاستخدام.<br />بكمیة أكثر من المطلوب: U.D &trade; إذا استخدمت زولامول<br />إذا كنت وضعت الكثیر من القطرات في العین أو ابتلعت أي من محتویات القطارة، فمن بین الآثار<br />الأخرى، فقد تشعر بالدوخة، وصعوبة في التنفس ، أو تشعر بأن معدل ضربات القلب قد تباطأ.فاتصل<br />بطبیبك على الفور.<br />:U.D &trade; إذا نسیت إستخدام زولامول<br />كما ھو موصوف لك من قبل الطبیب. U.D &trade; من الضروري أن تستخدم زولامول<br />إذا نسیت إحدى الجرعات فقم بإستخدامھا في أسرع وقت ممكن ولكن إذا كان قد حان موعد الجرعة التالیة<br />فقم بتفویت الجرعة التي نسیتھا وإرجع إلى جدول جرعاتك المعتاد.<br />لا تقم بوضع جرعة مضاعفة لتعویض ما قد تم نسیانھ من جرعات فردیة.</p><p>:U.D &trade; إذا توقفت عن إستخدام زولامول<br />إذا كنت ترغب في التوقف عن العلاج بھذا الدواء، اتصل بطبیبك أولاً. إذا كان لدیك أي أسئلة أخرى عن<br />إستخدام ھذا المستحضر، فإسأل طبیبك أو الصیدلي.</p>
        </div>
    </div>
    <div class="col-xs-12">
        <div class="clearfix">
            <label class="h2" for="SideEffectsAr">4. الأعراض الجانبية المحتملة</label>
        </div>
        <div class="m-r-60">
            <p>٤. التأثیرات الجانبیة المحتملة<br />مثل جمیع الأدویة، یمكن لھذا الدواء یسبب آثارا جانبیة، بالرغم من عدم تعرض جمیع الأشخاص لھا.<br />یمكنك دائماً الاستمرار في إستخدام قطرة العین إلا إذا كانت الآثار الجانبیة خطیرة. إذا كنت قلقاَ فقم<br />بدون التحدث إلى طبیبك. U.D &trade; بالتحدث إلى طبیبك أو الصیدلي. لا تقم بالتوقف عن إستخدام زولامول<br />&bull; تفاعلات تحسسیة بشكل عام تشمل تورم تحت الجلد والذي یمكن أن یحدث في مناطق مثل الوجھ<br />والأطراف ویمكن أن تسبب انسداد في القنوات الھوائیة والذي ینتج عنھ صعوبة في التنفس أو البلع، شرى<br />و حكة، طفح جلدي موضعي و عام، تفاعلات تحسسیة بشكل مفاجيء وحاد تھدد الحیاة.<br />یتم تعریف تردد الاثار الجانبیة المحتملة المدرجة أدناه باستخدام الاصطلاحات التالیة:<br />( شائع جدا (یؤثر على أكثر من ۱ مستخدم في ۱۰<br />( شائع (یؤثر على ۱ إلى ۱۰ مستخدمین في ۱۰۰<br />( غیر شائع (یؤثر على ۱ إلى ۱۰ مستخدمین في ۱,۰۰۰<br />( نادر(یؤثر على ۱ إلى ۱۰ مستخدمین في ۱۰,۰۰۰<br />غیر معروف (لا یمكن تقدیر تردده من البیانات المتاحة)<br />تم الإبلاغ عن الآثار الجانبیة الآتیة مع (دورزولامید /تیمولول) أو إحدى مكوناتھ سواء أثناء التجارب<br />السریریة أو خلال خبرة ما بعد التسویق:<br />آثار جانبیة شائعة جداً:<br />الشعور بحرقان ووخز في العین ومذاق غیر معتاد.<br />آثار جانبیة شائعة<br />احمرار في (و) حول العینین تدمیع أو حكة في العین وآثار على سطح العین، تورم و / أو تھیج في و حول<br />العین، والشعور بوجود شيء ما في العین (تقرح بالقرنیة) ، نقص حساسیة القرنیة &quot;أي عدم القدرة على<br />الشعور بوجود جسم ما في العین وعدم الشعور بالألم في العین&quot; ، ألم في العین، جفاف العین، عدم وضوح<br />الرؤیة، والصداع، والتھاب الجیوب الأنفیة شعور بالتوتر أو الامتلاء في الأنف، الشعور بالغثیان ، الضعف<br />/ التعب والإرھاق.<br />آثار جانبیة غیر شائعة<br />دوخة، اكتئاب، التھاب القزحیة، عدم وضوح الرؤیة، في بعض الحالات (بسبب انسحاب الدواء لعلاج<br />الانقباض المفرط لحدقة العین). بطء في ضربات القلب، والاغماء، صعوبة في التنفس (ضیق النفس)،عسر<br />الھضم، وحصوات الكلى.<br />آثار جانبیة نادرة<br />الذِئْبَةٌ الحُمَامِیَّةٌ المَجْموعِیَّة (مرض مناعي قد یسبب التھاب في الأعضاء الداخلیة من الجسم)، وخز أو تنمیل<br />في الیدین أو القدمین، واضطرابات في النوم، وكوابیس، فقدان الذاكرة، وزیادة في علامات وأعراض<br />الوھن العضلي الوبیل (اضطراب العضلات)، وانخفاض الدافع الجنسي، والسكتة الدماغیة، قصر نظر<br />مؤقت والذي قد ینتھي عندما یتم إیقاف العلاج، انفصال في طبقة تحت الشبكیة التي تحتوي على الأوعیة<br />الدمویة التالیة لجراحة ترشیح و التي قد تسبب اضطرابات بصریة، تدلى الجفون (جعل العین نصف<br />مغلقة)، الرؤیة المزدوجة، تقشر الجفن، تورم القرنیة (مع أعراض اضطرابات بصریة)، انخفاض الضغط<br />في العین، رنین ضوضاء في الأذن، انخفاض ضغط الدم، والتغیرات في إیقاع أو سرعة ضربات القلب،<br />وفشل القلب الاحتقاني (أمراض القلب مع ضیق في التنفس وتورم في القدمین والساقین بسبب تراكم<br />السوائل )، تورم (تراكم السوائل)، نقص الأوكسجین الدماغي (خفض إمدادات الدم إلى الدماغ)، ألم في<br />الصدر، خفقان ( تسارع و / أو عدم انتظام ضربات القلب)، نوبة قلبیة، ظاھرة رینود، تورم أو برودة<br />الیدین والقدمین وانخفاض تدفق الدورة الدمویة إلى الذراعین والساقین، تشنجات الساق و / أو ألم في الساق<br />عند المشي (العرج)، ضیق في التنفس، فشل الجھاز التنفسي، التھاب الأنف، نزیف الأنف، انقباض الشعب<br />الھوائیة في الرئتین والسعال وتھیج الحلق، جفاف الفم، الإسھال، التھاب الجلد التماسي، تساقط الشعر ،<br />الطفح الجلدي مع ظھورلون أبیض فضي ( طفح صدافي الجلدي) ومرض بیروني (والذي قد یؤدي إلى<br />انحناء القضیب)، وردود فعل تحسسیة مثل الطفح الجلدي، الشرى، الحكة، وفي حالات نادرة یمكن أن<br />یحدث تورم في الشفتین والعینین والفم، أزیز التنفس، أو تفاعلات جلدیة شدیدة ( متلازمة جونسون ستیفنز،<br />انحلال البشرة السمي).<br />مثل باقي الأدویة الأخرى التي یتم إعطاؤھا في العین، یتم امتصاص تیمولول في الدم .وھذا قد یتسبب في<br />حدوث آثار جانبیة مماثلة لتلك التي تظھر مع إستخدام حاصرات بیتا التي تؤخذ عن طریق الفم .معدل<br />حدوث الآثار الجانبیة بعد إستخدام الدواء عن طریق العین أقل من تلك التي تحدث عندما یتم إستخدام<br />الأدویة على سبیل المثال، عن طریق الفم أو الحقن<br />شوھدت آثار جانبیة إضافیة تشمل ردود الفعل التحسسیة مع فئة من حاصرات بیتا عندما تستخدم لعلاج<br />حالة العین.<br />معدل غیر معروف:<br />&bull; انخفاض مستویات السكر في الدم، وفشل في عضلة القلب، آلام في المعدة وتقیؤ وألم في العضلات لا<br />ینجم عن ممارسة الریاضة، العجز الجنسي.<br />إذا لاحظت تحول أي من الآثار جانبیة إلى مرحلة أكثر خطورة أو إذا ظھرت أیة آثار جانبیة أخرى غیر<br />مدرجة في ھذه النشرة فیرجى إخبار طبیبك أو الصیدلي بھا لا سیما إذا كنت تواجھ أي تغییرات / اضطراب<br />بعد جراحة العیون. U.D &trade; في الرؤیة عند إستخدام زولامول<br />&nbsp;</p>
        </div>
    </div>
    <div class="col-xs-12">
        <div class="clearfix">
            <label class="h2" for="StorageConditionsAr">5. طريقة تخزين المستحضر</label>
        </div>
        <div class="m-r-60">
            <p>&bull; یحفظ بعیداً عن متناول و مرأى الأطفال.<br />&bull; یحفظ في درجة حرارة لا تزید عن ۳۰ درجة مئویة.<br />&bull; لا یجمد. یحفظ في الأغلفة من أجل الحمایة من الضوء.<br />&bull; لا تستخدم أكثر من ۰۳ یوما بعد فتح الغلاف الألومنیوم.<br />&bull; استخدم قطرة العین مباشرة بعد فتح حاویة الجرعة أحادیة الإستخدام.<br />&bull; تخلص من الحاویة المفتوحة مع أي محتویات متبقیة مباشرة بعد الاستخدام.<br />. EXP بعد انتھاء تاریخ الصلاحیة المدون على العبوة الكرتونیة بعد كلمة U.D &trade; &bull; لا تستخدم زولامول<br />&bull; تخلص من حاویة الجرعة أحادیة الإستخدام مع أي محلول متبقى بھا فوراً بعد أول إستخدام.<br />&bull; لا یتم التخلص من الأدویة عن طریق میاه الصرف أو النفایات المنزلیة. إسأل الصیدلي عن طریقة<br />التخلص من الأدویة الغیر مرغوب فیھا فسوف تساعد ھذه الإجراءات على حمایة البیئة.<br />&nbsp;</p>
        </div>
    </div>
    <div class="col-xs-12">
        <label style="float: right">6. معلومات أخرى</label>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label class="h2" for="IngredientsAr">أ‌. على ماذا يحتوي هذا المستحضر</label>
        </div>
        <div class="m-r-60">
            <p>U.D &trade; ما ھي مكونات زولامول<br />&bull; المواد الفعالة ھي الدورزولامید والتیمولول.<br />كل ۱ مل یحتوي على:<br />۲۲,۲٥ ملغ ھایدروكلورید الدورزولامید (یكافئ ۲۰ ملغ دورزولامید) و ٦٫۸۳ ملغ مالیات التیمولول<br />(یكافئ ٥ ملغ تیمولول).<br />&bull; المكونات الأخرى ھي: ھیدروكسي إیثیل سلیلوز، مانیتول، سترات الصودیوم، صودیوم ھیدروكسید و/أو<br />و ماء للحقن. (pH حامض الھیدروكلوریك ( لضبط درجة الحموضة<br />&nbsp;</p>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label class="h2" for="ShapeAndContentsAr">ب‌. كيف يبدو شكل هذا المستحضر وماهي محتويات العلبة</label>
        </div>
        <div class="m-r-60">
            <p dir="ltr">ھو محلول رائق عدیم اللون. U.D &trade; &bull; زولامول<br />عبوة بھا ۳۰ جرعة أحادیة الإستخدام، من البولي ایثیلین منخفض الكثافة، محكمة U.D &trade; &bull; زولامول<br />الغلق، خالیة من المواد الحافظة، الجرعات مرتبة في ٦ أغلفة معدنیة كل منھا یحتوي علي ٥ جرعات<br />أحادیة الإستخدام.<br />كل جرعة أحادیة بداخلھا ۰٫۲ مل من قطرة العین.<br />&nbsp;</p>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label class="h2" for="ManufacturingAndMarketingAr">ت‌. الشركة المصنعة ومالك حق التسويق</label>
        </div>
        <div class="m-r-60">
            <p>شركة مصنع جمجوم للأدویة ،<br />جدة، منطقة مكة، المملكة العربیة السعودیة<br />+۹٦٦-۱۲- الھاتف: ٦۰۸۱۱۱۱<br />+۹٦٦-۱۲- فاكس: ٦۰۸۱۲۲۲<br />www.jamjoompharma.com : الموقع الإلكتروني<br />للإبلاغ عن أي أثار جانبیھ:<br />&bull; المملكة العربیة السعودیة:<br />:(NPC) المركز الوطني للتیقظ الدوائي<br />+۹٦٦-۱۱-۲۰٥- فاكس: ۷٦٦۲ o<br />مركز اتصال الھیئة العامة للغذاء والدواء: ۱۹۹۹۹ o<br />npc.drug@sfda.gov.sa : برید إلكتروني o<br />https://ade.sfda.gov.sa : الموقع الالكتروني o<br />&nbsp;</p>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label class="h2" for="RevisionNoteAr">ث‌. تمت مراجعة هذه النشرة في التاريخ الذي تمت فيه مراجعة النشرة بالشهر والسنة</label>
        </div>
        <div class="m-r-60">
            - الرجاء الاتصال بالمؤسسات و الھیئات الوطنیة في كل دولة.
۲۰۲٤ . رقم النسخة ۰۲ / تم مراجعة ھذه النشرة في ۱۱
        </div>
    </div>
</div>
    </div>
    <div id="M-div" class="box-data">


    <div class="p-20 text-center font-22">
            <div class="p-10 bg-light-blue font-15 m-t-20 m-b-20 ltr"><i class="fa fa-info-circle"></i>&nbsp;Read this leaflet carefully before you start using this product as it contains important information for you</div>
    </div>
<div class="row clearfix ltr">

    <div class="col-xs-12">
        <div class="clearfix">
            <label style="float: left" for="MedicinalName">1. NAME OF THE MEDICINAL PRODUCT </label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                Xolamol Eye Drops UD
            </div>
        </div>
    </div>
    <div class="col-xs-12">
        <div class="clearfix">
            <label style="float: left" for="QualitativeQuantitativeComposition">2. QUALITATIVE AND QUANTITATIVE COMPOSITION </label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                Each ml contains: Dorzolamide Hydrochloride 22.25 mg (equivalent to Dorzolamide 20 mg) and
Timolol Maleate 6.83 mg (equivalent to Timolol 5 mg).
For a full list of excipients, see section 6.1.
            </div>
        </div>
    </div>
    <div class="col-xs-12">
        <div class="clearfix">
            <label style="float: left" for="DosageForm">3. PHARMACEUTICAL FORM </label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                Clear colorless solution free from visible particles, filled in LDPE minims.
Single-use, sterile eye drops.
            </div>
        </div>
    </div>
    <div class="col-xs-12">
        <label style="float: left">4. CLINICAL PARTICULARS</label>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="TherapeuticIndications">4.1 Therapeutic Indications</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>Indicated in the treatment of elevated intraocular pressure (IOP) in patients with open-angle glaucoma or pseudoexfoliative glaucoma when topical beta-blocker monotherapy is not sufficient.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="PosologyAndMethodAdministration">4.2 Posology And Method Administration</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>The dose is one drop in the conjunctival sac of the affected eye(s) two times daily.<br />If another topical ophthalmic agent is being used, Dorzolamide / Timolol and the other agent should be administered at least ten minutes apart.<br />Patients should be instructed to wash their hands before use and avoid allowing the tip of the container to come into contact with the eye or surrounding structures.<br />Patients should also be instructed that ocular solutions, if handled improperly, can become contaminated by common bacteria known to cause ocular infections. Serious damage to the eye and subsequent loss of vision may result from using contaminated solutions.<br />When using nasolacrimal occlusion or closing the eyelids for 2 minutes, the systemic absorption is reduced. This may result in a decrease in systemic side effects and an increase in local activity.</p><p>Paediatric population<br />Efficacy in paediatric patients has not been established.<br />Safety in paediatric patients below the age of two years has not been established. (For information regarding safety in paediatric patients 2 and &lt; 6 years of age, see section 5.1).</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="Contraindications">4.3 Contraindications</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                Dorzolamide / Timolol is contraindicated in patients with:
• reactive airway disease, including bronchial asthma or a history of bronchial asthma, or severe
chronic obstructive pulmonary disease
• sinus bradycardia, sick sinus syndrome, sino-atrial block, second or third degree atrioventricular
block not controlled with pace-maker. Overt cardiac failure, cardiogenic shock 
• severe renal impairment (CrCl < 30 ml/min) or hyperchloraemic acidosis
• hypersensitivity to one or both active substances or to any of the excipients.
The above are based on the components and are not unique to the combination.
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="SpecialWarnings">4.4. Special warnings and precautions for use</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>Cardiovascular/Respiratory Reactions<br />Like other topically applied ophthalmic agents Timolol maleate is absorbed systemically. Due to betaadrenergic component, timolol maleate, the same types of cardiovascular, pulmonary and other adverse reactions seen with systemic beta-adrenergic blocking agents may occur. Incidence of systemic ADRs after topical ophthalmic administration is lower than for systemic administration. To reduce the systemic absorption, see section 4.2.<br />Cardiac disorders<br />In patients with cardiovascular diseases (e.g. coronary heart disease, Prinzmetal&#39;s angina and cardiac failure) and hypotension therapy with beta-blockers should be critically assessed and the therapy with other active substances should be considered. Patients with cardiovascular diseases should be watched for signs of deterioration of these diseases and of adverse reactions.</p><p>Due to its negative effect on conduction time, beta-blockers should only be given with caution to patients with first degree heart block.<br />Vascular disorders<br />Patients with severe peripheral circulatory disturbance/disorders (i.e. severe forms of Raynaud&#39;s disease or Raynaud&#39;s syndrome) should be treated with caution.<br />Respiratory Disorders<br />Respiratory reactions, including death due to bronchospasm in patients with asthma have been reported following administration of some ophthalmic beta-blockers.<br />Dorzolamide / Timolol should be used with caution, in patients with mild/moderate chronic obstructive pulmonary disease (COPD) and only if the potential benefit outweighs the potential risk.<br />Hepatic Impairment<br />Dorzolamide / Timolol has not been studied in patients with hepatic impairment and should therefore be used with caution in such patients.<br />Immunology and Hypersensitivity<br />As with other topically-applied ophthalmic agents, this medicinal product may be absorbed&nbsp;systemically.<br />Dorzolamide contains a sulfonamido group, which also occurs in sulphonamides. Therefore, the same types of adverse reactions found with systemic administration of sulphonamides may occur with topical administration, including severe reactions such as Stevens-Johnson syndrome and toxic<br />epidermal necrolysis. If signs of serious reactions or hypersensitivity occur, discontinue use of this preparation.<br />Local ocular adverse effects, similar to those observed with dorzolamide hydrochloride eye drops, have been seen with dorzolamide timolol eye drops solution. If such reactions occur, discontinuation of Dorzolamide / Timolol should be considered.<br />While taking beta-blockers, patients with a history of atopy or a history of severe anaphylactic reaction to a variety of allergens may be more reactive to accidental, diagnostic, or therapeutic repeated challenge with such allergens and may be unresponsive to the usual doses of adrenaline used to treat anaphylactic reactions.<br />Concomitant Therapy<br />The effect on intra-ocular pressure or the known effects of systemic beta-blockade may be potentiated when timolol maleate is given to the patients already receiving a systemic beta-blocking agent. The response of these patients should be closely observed. The use of two topical beta-adrenergic blocking<br />agents is not recommended (see section section 4.5).<br />The use of dorzolamide and oral carbonic anhydrase inhibitors is not recommended.<br />Withdrawal of Therapy<br />As with systemic beta-blockers, if discontinuation of ophthalmic timolol is needed in patients with&nbsp;coronary heart disease, therapy should be withdrawn gradually<br />Additional Effects of Beta-Blockade<br />Hypoglycaemia/diabetes<br />Beta-blockers should be administered with caution in patients subject to spontaneous hypoglycaemia or to patients with labile diabetes, as beta-blockers may mask the signs and symptoms of acute<br />hypoglycaemia.<br />Beta-blockers may also mask the signs of hyperthyroidism. Abrupt withdrawal of beta-blocker therapy may precipitate a worsening of symptoms.<br />Corneal diseases<br />Ophthalmic &beta;-blockers may induce dryness of eyes. Patients with corneal diseases should be treated with caution.<br />Surgical anaesthesia<br />&beta;-blocking ophthalmological preparations may block systemic &beta;-agonist effects e.g. of adrenaline. The&nbsp;anaesthesiologist should be informed when the patient is receiving timolol maleate.<br />Therapy with beta-blockers may aggravate symptoms of myasthenia gravis.<br />Additional Effects of Carbonic Anhydrase Inhibition</p><p>Therapy with oral carbonic anhydrase inhibitors has been associated with urolithiasis as a result of acid-base disturbances, especially in patients with a prior history of renal calculi. Although no acidbase disturbances have been observed with Dorzolamide / Timolol, urolithiasis has been reported<br />infrequently. Because Dorzolamide / Timolol contains a topical carbonic anhydrase inhibitor that is absorbed systemically, patients with a prior history of renal calculi may be at increased risk of urolithiasis while using Dorzolamide / Timolol.<br />Other<br />The management of patients with acute angle-closure glaucoma requires therapeutic interventions in addition to ocular hypotensive agents. Dorzolamide / Timolol has not been studied in patients with acute angle-closure glaucoma.<br />Corneal oedema and irreversible corneal decompensation have been reported in patients with preexisting chronic corneal defects and/or a history of intraocular surgery while using dorzolamide. There is an increased potential for developing corneal oedema in patients with low endothelial cell counts.<br />Precautions should be used when prescribing Dorzolamide / Timolol to these groups of patients.<br />Choroidal detachment has been reported with administration of aqueous suppressant therapy (e.g.<br />timolol, acetazolamide) after filtration procedures<br />As with the use of other antiglaucoma drugs, diminished responsiveness to ophthalmic timolol maleate after prolonged therapy has been reported in some patients. However, in clinical studies in which 164 patients have been followed for at least three years, no significant difference in mean intraocular<br />pressure has been observed after initial stabilisation.<br />Contact Lens Use<br />Dorzolamide / Timolol contains the preservative benzalkonium chloride, which may cause eye irritation. Remove contact lenses prior to application and wait at least 15 minutes before reinsertion.<br />Benzalkonium chloride is known to discolour soft contact lenses.<br />Paediatric population<br />See section 5.1.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="InteractionsOtherMedicines">4.5. Interactions with other medicinal products</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>Specific drug interaction studies have not been performed with Dorzolamide / Timolol.<br />In clinical studies, dorzolamide timolol eye drops solution was used concomitantly with the following<br />systemic medications without evidence of adverse interactions: ACE-inhibitors, calcium channel<br />blockers, diuretics, non-steroidal anti-inflammatory drugs including aspirin, and hormones (e.g.<br />oestrogen, insulin, thyroxine).<br />There is a potential for additive effects resulting in hypotension and/or marked bradycardia when<br />ophthalmic beta-blockers solution is administered concomitantly with oral calcium channel blockers,<br />catecholamine-depleting medicines or beta-adrenergic blocking agents, antiarrhythmics (including<br />amiodarone), digitalis glycosides, parasympathomimetics, narcotics, guanethidine and monoamine<br />oxidase (MAO) inhibitors.<br />Potentiated systemic beta-blockade (e.g., decreased heart rate, depression) has been reported during<br />combined treatment with CYP2D6 inhibitors (e.g. quinidine, fluoxetine, paroxetine) and timolol.<br />Although dorzolamide timolol eye drops solution alone has little or no effect on pupil size, mydriasis<br />resulting from concomitant use of ophthalmic beta-blockers and adrenaline (epinephrine) has been<br />reported occasionally.<br />Beta-blockers may increase the hypoglycaemic effect of antidiabetic agents.<br />Oral beta-adrenergic blocking agents may exacerbate the rebound hypertension which can follow the<br />withdrawal of clonidine.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="FertilityAndPregnantWarnings">4.6. Fertility, pregnancy and lactation</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>Use During Pregnancy<br />Dorzolamide / Timolol Tubilux should not be used during pregnancy.<br />Dorzolamide<br />No adequate clinical data in exposed pregnancies are available. In rabbits, dorzolamide produced&nbsp;teratogenic effect at maternotoxic doses (see Section 5.3).<br />Timolol</p><p>There are no adequate data for the use of timolol maleate in pregnant women. Timolol maleate should not be used during pregnancy unless clearly necessary.<br />To reduce the systemic absorption, see section 4.2.<br />Epidemiological studies have not revealed malformative effects but show a risk for intra uterine growth retardation when beta-blockers are administered by the oral route. In addition, signs and symptoms of beta-blockade (e.g. bradycardia, hypotension, respiratory distress and hypoglycaemia)<br />have been observed in the neonate when beta-blockers have been administered until delivery.<br />If Dorzolamide / Timolol is administered until delivery, the neonate should be carefully monitored during the first days of life.<br />Use During Lactation<br />Dorzolamide<br />It is not known whether dorzolamide is excreted in human milk. In lactating rats receiving dorzolamide, decreases in the body weight gain of offspring were observed.<br />Timolol<br />Beta-blockers are excreted in breast milk. However, at therapeutic doses of timolol maleate in eye drops it is not likely that sufficient amounts would be present in breast milk to produce clinical symptoms of beta-blockade in the infant. To reduce the systemic absorption, see section 4.2.<br />If treatment with Dorzolamide / Timolol is required, then breast feeding is not recommended.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="EffectsAbilityDriveMachines">4.7. Effects on ability to drive and use machines</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>No studies on the effects on the ability to drive and use machines have been performed. Possible side<br />effects such as blurred vision may affect some patients&#39; ability to drive and/or operate machinery.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="UndesirableEffects">4.8. Undesirable effects</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>In clinical studies for dorzolamide timolol eye drops solution the observed adverse reactions have been&nbsp;consistent with those that were reported previously with dorzolamide hydrochloride and/or timolol maleate.<br />During clinical studies, 1035 patients were treated with dorzolamide timolol eye drops solution.<br />Approximately 2.4% of all patients discontinued therapy with dorzolamide timolol eye drops solution&nbsp;because of local ocular adverse reactions, approximately 1.2% of all patients discontinued because of local adverse reactions suggestive of allergy or hypersensitivity (such as lid inflammation and<br />conjunctivitis).<br />Like other topically applied ophthalmic drugs, timolol maleate is absorbed into the systemic circulation. This may cause similar undesirable effects as seen with systemic beta-blocking agents. Incidence of systemic ADRs after topical ophthalmic administration is lower than for systemic administration.<br />The following adverse reactions have been reported with dorzolamide timolol eye drops solution or one of its components either during clinical trials or during post-marketing experience:<br />[Very Common: ( 1/10), Common: ( 1/100 to &lt;1/10), Uncommon: 1/1000 to &lt;1/100), and Rare: (1/10,000 to &lt;1/1000) , Not known (cannot be estimated from the available data)]</p><p>&nbsp;</p><table cellpadding="2" cellspacing="0" border="1" style="width:691px"><tbody><tr><td colspan="" rowspan=""><p><strong>System Organ Class (MedDRA)</strong></p></td><td colspan="" rowspan=""><p><strong>Formulation</strong></p></td><td colspan="" rowspan=""><p><strong>Very Common</strong></p></td><td colspan="" rowspan=""><p><strong>Common</strong></p></td><td colspan="" rowspan=""><p><strong>Uncommon</strong></p></td><td colspan="" rowspan=""><p><strong>Rare</strong></p></td><td colspan="" rowspan=""><p><strong>Not Known**</strong></p></td></tr><tr><td colspan="" rowspan=""><p><strong>Immune system disorders</strong></p></td><td colspan="" rowspan=""><p><strong>dorzolamide<br />timolol eye drops<br />solution</strong></p></td><td colspan="" rowspan=""><p>&nbsp;</p></td><td colspan="" rowspan=""><p>&nbsp;</p></td><td colspan="" rowspan=""><p>&nbsp;</p></td><td colspan="" rowspan=""><p>signs and symptoms of systemic allergic reactions, including angioedema, urticaria, pruritus, rash, anaphylaxis</p></td><td colspan="" rowspan=""><p>&nbsp;</p></td></tr><tr><td colspan="" rowspan=""><p>&nbsp;</p></td><td colspan="" rowspan=""><p><strong>Timolol maleate eye drops, solution</strong></p></td><td colspan="" rowspan=""><p>&nbsp;</p></td><td colspan="" rowspan=""><p>&nbsp;</p></td><td colspan="" rowspan=""><p>&nbsp;</p></td><td colspan="" rowspan=""><p>signs and symptoms of allergic reactions including angioedema, urticaria, localised and generalised rash, anaphylaxis</p></td><td colspan="" rowspan=""><p>pruritus</p></td></tr><tr><td colspan="" rowspan=""><p><strong>Metabolism and nutrition disorders</strong></p></td><td colspan="" rowspan=""><p><strong>Timolol maleate eye drops, solution</strong></p></td><td colspan="" rowspan=""><p>&nbsp;</p></td><td colspan="" rowspan=""><p>&nbsp;</p></td><td colspan="" rowspan=""><p>&nbsp;</p></td><td colspan="" rowspan=""><p>&nbsp;</p></td><td colspan="" rowspan=""><p>hypoglycaemia</p></td></tr><tr><td colspan="" rowspan=""><p><strong>Psychiatric disorders</strong></p></td><td colspan="" rowspan=""><p><strong>Timolol maleate eye drops, solution</strong></p></td><td colspan="" rowspan=""><p>&nbsp;</p></td><td colspan="" rowspan=""><p>&nbsp;</p></td><td colspan="" rowspan=""><p>depression*</p></td><td colspan="" rowspan=""><p>insomnia*, nightmares*, memory loss</p></td><td colspan="" rowspan=""><p>hallucination</p></td></tr><tr><td colspan="" rowspan=""><p><strong>Nervous system disorders</strong></p></td><td colspan="" rowspan=""><p><strong>Dorzolamide hydrochloride eye drops, solution</strong></p></td><td colspan="" rowspan=""><p>&nbsp;</p></td><td colspan="" rowspan=""><p>headache*</p></td><td colspan="" rowspan=""><p>&nbsp;</p></td><td colspan="" rowspan=""><p>dizziness*, paraesthesia*</p></td><td colspan="" rowspan=""><p>&nbsp;</p></td></tr><tr><td colspan="" rowspan=""><p>&nbsp;</p></td><td colspan="" rowspan=""><p><strong>Timolol maleate eye drops, solution</strong></p></td><td colspan="" rowspan=""><p>&nbsp;</p></td><td colspan="" rowspan=""><p>headache*</p></td><td colspan="" rowspan=""><p>dizziness*, syncope*</p></td><td colspan="" rowspan=""><p>paraesthesia*, increase in signs and symptoms of myasthenia gravis, decreased libido*, cerebrovascular accident*, cerebral ischaemia</p></td><td colspan="" rowspan=""><p>&nbsp;</p></td></tr><tr><td colspan="" rowspan=""><p><strong>Eye disorders</strong></p></td><td colspan="" rowspan=""><p><strong>dorzolamide<br />timolol eye drops<br />solution</strong></p></td><td colspan="" rowspan=""><p>burning and stinging</p></td><td colspan="" rowspan=""><p>conjunctival injection, blurred vision, corneal erosion, ocular itching, tearing</p></td><td colspan="" rowspan=""><p>&nbsp;</p></td><td colspan="" rowspan=""><p>&nbsp;</p></td><td colspan="" rowspan=""><p>&nbsp;</p></td></tr><tr><td colspan="" rowspan=""><p>&nbsp;</p></td><td colspan="" rowspan=""><p><strong>Dorzolamide hydrochloride eye drops, solution</strong></p></td><td colspan="" rowspan=""><p>&nbsp;</p></td><td colspan="" rowspan=""><p>eyelid inflammation*, eyelid irritation*</p></td><td colspan="" rowspan=""><p>iridocyclitis*</p></td><td colspan="" rowspan=""><p>irritation including redness*, pain*, eyelid crusting*, transient myopia (which resolved upon discontinuation of therapy), corneal oedema*, ocular hypotony*, choroidal detachment (following filtration surgery)*</p></td><td colspan="" rowspan=""><p>foreign body sensation in eye</p></td></tr><tr><td colspan="" rowspan=""><p>&nbsp;</p></td><td colspan="" rowspan=""><p><strong>Timolol maleate eye drops, solution</strong></p></td><td colspan="" rowspan=""><p>&nbsp;</p></td><td colspan="" rowspan=""><p>signs and symptoms of ocular irritation including blepharitis*, keratitis*, decreased corneal sensitivity, and dry eyes*</p></td><td colspan="" rowspan=""><p>visual disturbances including refractive changes (due to withdrawal of miotic therapy in some cases)*</p></td><td colspan="" rowspan=""><p>ptosis, diplopia, choroidal detachment following filtration surgery* (see Special warning and precautions for use 4.4)</p></td><td colspan="" rowspan=""><p>itching, tearing, redness, blurred vision, corneal erosion</p></td></tr><tr><td colspan="" rowspan=""><p><strong>Ear and labyrinth disorders</strong></p></td><td colspan="" rowspan=""><p><strong>Timolol maleate eye drops, solution</strong></p></td><td colspan="" rowspan=""><p>&nbsp;</p></td><td colspan="" rowspan=""><p>&nbsp;</p></td><td colspan="" rowspan=""><p>&nbsp;</p></td><td colspan="" rowspan=""><p>tinnitus*</p></td><td colspan="" rowspan=""><p>&nbsp;</p></td></tr><tr><td colspan="" rowspan=""><p><strong>Cardiac disorders</strong></p></td><td colspan="" rowspan=""><p><strong>Timolol maleate eye drops, solution</strong></p></td><td colspan="" rowspan=""><p>&nbsp;</p></td><td colspan="" rowspan=""><p>&nbsp;</p></td><td colspan="" rowspan=""><p>bradycardia*</p></td><td colspan="" rowspan=""><p>chest pain*, palpitation*, oedema*, arrhythmia*, congestive heart failure*, cardiac arrest*, heart block</p></td><td colspan="" rowspan=""><p>atrioventricular block, cardiac failure</p></td></tr><tr><td colspan="" rowspan="">&nbsp;</td><td colspan="" rowspan=""><p><strong>Dorzolamide hydrochloride eye drops, solution</strong></p></td><td colspan="" rowspan=""><p>&nbsp;</p></td><td colspan="" rowspan=""><p>&nbsp;</p></td><td colspan="" rowspan="">&nbsp;</td><td colspan="" rowspan="">&nbsp;</td><td colspan="" rowspan=""><p>palpitations</p></td></tr><tr><td colspan="" rowspan=""><p><strong>Vascular disorders</strong></p></td><td colspan="" rowspan=""><p><strong>Timolol maleate eye drops, solution</strong></p></td><td colspan="" rowspan=""><p>&nbsp;</p></td><td colspan="" rowspan=""><p>&nbsp;</p></td><td colspan="" rowspan=""><p>&nbsp;</p></td><td colspan="" rowspan=""><p>hypotension*, claudication, Raynaud&#39;s phenomenon*, cold hands and feet*</p></td><td colspan="" rowspan=""><p>&nbsp;</p></td></tr><tr><td colspan="" rowspan=""><p><strong>Respiratory, thoracic, and mediastinal disorders</strong></p></td><td colspan="" rowspan=""><p><strong>dorzolamide<br />timolol eye drops<br />solution</strong></p></td><td colspan="" rowspan=""><p>&nbsp;</p></td><td colspan="" rowspan=""><p>sinusitis</p></td><td colspan="" rowspan=""><p>&nbsp;</p></td><td colspan="" rowspan=""><p>shortness of breath, respiratory failure, rhinitis, rarely bronchospasm</p></td><td colspan="" rowspan=""><p>&nbsp;</p></td></tr><tr><td colspan="" rowspan=""><p>&nbsp;</p></td><td colspan="" rowspan=""><p><strong>Dorzolamide hydrochloride eye drops, solution</strong></p></td><td colspan="" rowspan=""><p>&nbsp;</p></td><td colspan="" rowspan=""><p>&nbsp;</p></td><td colspan="" rowspan=""><p>&nbsp;</p></td><td colspan="" rowspan=""><p>epistaxis*</p></td><td colspan="" rowspan=""><p>dyspnoea</p></td></tr><tr><td colspan="" rowspan=""><p>&nbsp;</p></td><td colspan="" rowspan=""><p><strong>Timolol maleate eye drops, solution</strong></p></td><td colspan="" rowspan=""><p>&nbsp;</p></td><td colspan="" rowspan=""><p>&nbsp;</p></td><td colspan="" rowspan=""><p>dyspnoea*</p></td><td colspan="" rowspan=""><p>bronchospasm (predominantly in patients with pre-existing bronchospastic disease)*, respiratory failure, cough*</p></td><td colspan="" rowspan=""><p>&nbsp;</p></td></tr><tr><td colspan="" rowspan=""><p><strong>Gastrointestinal disorders</strong></p></td><td colspan="" rowspan=""><p><strong>dorzolamide<br />timolol eye drops<br />solution</strong></p></td><td colspan="" rowspan=""><p>dysgeusia</p></td><td colspan="" rowspan=""><p>&nbsp;</p></td><td colspan="" rowspan=""><p>&nbsp;</p></td><td colspan="" rowspan=""><p>&nbsp;</p></td><td colspan="" rowspan=""><p>&nbsp;</p></td></tr><tr><td colspan="" rowspan=""><p>&nbsp;</p></td><td colspan="" rowspan=""><p><strong>Dorzolamide hydrochloride eye drops, solution</strong></p></td><td colspan="" rowspan=""><p>&nbsp;</p></td><td colspan="" rowspan=""><p>nausea*</p></td><td colspan="" rowspan=""><p>&nbsp;</p></td><td colspan="" rowspan=""><p>throat irritation, dry mouth*</p></td><td colspan="" rowspan=""><p>&nbsp;</p></td></tr><tr><td colspan="" rowspan=""><p>&nbsp;</p></td><td colspan="" rowspan=""><p><strong>Timolol maleate eye drops, solution</strong></p></td><td colspan="" rowspan=""><p>&nbsp;</p></td><td colspan="" rowspan=""><p>&nbsp;</p></td><td colspan="" rowspan=""><p>nausea*, dyspepsia*</p></td><td colspan="" rowspan=""><p>diarrhoea, dry mouth*</p></td><td colspan="" rowspan=""><p>dysgeusia, abdominal pain, vomiting</p></td></tr><tr><td colspan="" rowspan=""><p><strong>Skin and subcutaneous tissue disorders</strong></p></td><td colspan="" rowspan=""><p><strong>dorzolamide<br />timolol eye drops<br />solution</strong></p></td><td colspan="" rowspan=""><p>&nbsp;</p></td><td colspan="" rowspan=""><p>&nbsp;</p></td><td colspan="" rowspan=""><p>&nbsp;</p></td><td colspan="" rowspan=""><p>contact dermatitis, Stevens-Johnson syndrome, toxic epidermal necrolysis</p></td><td colspan="" rowspan=""><p>&nbsp;</p></td></tr><tr><td colspan="" rowspan=""><p>&nbsp;</p></td><td colspan="" rowspan=""><p><strong>Dorzolamide hydrochloride eye drops, solution</strong></p></td><td colspan="" rowspan=""><p>&nbsp;</p></td><td colspan="" rowspan=""><p>&nbsp;</p></td><td colspan="" rowspan=""><p>&nbsp;</p></td><td colspan="" rowspan=""><p>rash*</p></td><td colspan="" rowspan=""><p>&nbsp;</p></td></tr><tr><td colspan="" rowspan=""><p>&nbsp;</p></td><td colspan="" rowspan=""><p><strong>Timolol maleate eye drops, solution</strong></p></td><td colspan="" rowspan=""><p>&nbsp;</p></td><td colspan="" rowspan=""><p>&nbsp;</p></td><td colspan="" rowspan=""><p>&nbsp;</p></td><td colspan="" rowspan=""><p>alopecia*, psoriasiform rash or exacerbation of psoriasis*</p></td><td colspan="" rowspan=""><p>skin rash</p></td></tr><tr><td colspan="" rowspan=""><p><strong>Musculoskeletal and connective tissue disorders</strong></p></td><td colspan="" rowspan=""><p><strong>Timolol maleate eye drops, solution</strong></p></td><td colspan="" rowspan=""><p>&nbsp;</p></td><td colspan="" rowspan=""><p>&nbsp;</p></td><td colspan="" rowspan=""><p>&nbsp;</p></td><td colspan="" rowspan=""><p>systemic lupus erythematosus</p></td><td colspan="" rowspan=""><p>myalgia</p></td></tr><tr><td colspan="" rowspan=""><p><strong>Renal and urinary disorders</strong></p></td><td colspan="" rowspan=""><p><strong>dorzolamide<br />timolol eye drops<br />solution</strong></p></td><td colspan="" rowspan=""><p>&nbsp;</p></td><td colspan="" rowspan=""><p>&nbsp;</p></td><td colspan="" rowspan=""><p>urolithiasis</p></td><td colspan="" rowspan=""><p>&nbsp;</p></td><td colspan="" rowspan=""><p>&nbsp;</p></td></tr><tr><td colspan="" rowspan=""><p><strong>Reproductive system and breast disorders</strong></p></td><td colspan="" rowspan=""><p><strong>Timolol maleate eye drops, solution</strong></p></td><td colspan="" rowspan=""><p>&nbsp;</p></td><td colspan="" rowspan=""><p>&nbsp;</p></td><td colspan="" rowspan=""><p>&nbsp;</p></td><td colspan="" rowspan=""><p>Peyronie&#39;s disease*, decreased libido</p></td><td colspan="" rowspan=""><p>sexual dysfunction</p></td></tr><tr><td colspan="" rowspan=""><p><strong>General disorders and administration site conditions</strong></p></td><td colspan="" rowspan=""><p><strong>Dorzolamide hydrochloride eye drops, solution</strong></p></td><td colspan="" rowspan=""><p>&nbsp;</p></td><td colspan="" rowspan=""><p>asthenia/ fatigue*</p></td><td colspan="" rowspan=""><p>&nbsp;</p></td><td colspan="" rowspan=""><p>&nbsp;</p></td><td colspan="" rowspan=""><p>&nbsp;</p></td></tr><tr><td colspan="" rowspan=""><p>&nbsp;</p></td><td colspan="" rowspan=""><p><strong>Timolol maleate eye drops, solution</strong></p></td><td colspan="" rowspan=""><p>&nbsp;</p></td><td colspan="" rowspan=""><p>&nbsp;</p></td><td colspan="" rowspan=""><p>asthenia/ fatigue*</p></td><td colspan="" rowspan=""><p>&nbsp;</p></td><td colspan="" rowspan=""><p>&nbsp;</p></td></tr></tbody></table><p>*These adverse reactions were also observed with dorzolamide timolol eye drops solution during post-marketing experience.</p><p>**Additional adverse reactions have been seen with ophthalmic beta-blockers and may potentially occur with Dorzolamide /Timolol</p><p>To report any side effect(s):<br />&bull; Saudi Arabia:<br />The National Pharmacovigilance and Drug Safety Centre (NPC)<br />Fax: +966-11-205-7662<br />SFDA Call Center: 19999<br />E-mail: npc.drug@sfda.gov.sa<br />Website: https://ade.sfda.gov.sa<br />&bull; Other GCC States:<br />&minus; Please contact the relevant competent authority</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="Overdoes">4.9. Overdoes</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>No data are available in humans in regard to overdose by accidental or deliberate ingestion of<br />Dorzolamide / Timolol.<br />Symptoms<br />There have been reports of inadvertent overdoses with timolol maleate ophthalmic solution resulting<br />in systemic effects similar to those seen with systemic beta adrenergic blocking agents such as<br />dizziness, headache, shortness of breath, bradycardia, bronchospasm, and cardiac arrest. The most<br />common signs and symptoms to be expected with overdoses of dorzolamide are electrolyte<br />imbalance, development of an acidosis state, and possibly central nervous system effects.<br />Only limited information is available with regard to human overdose by accidental or deliberate<br />ingestion of dorzolamide hydrochloride. With oral ingestion, somnolence has been reported. With<br />topical application the following have been reported: nausea, dizziness, headache, fatigue, abnormal<br />dreams, and dysphagia.<br />Treatment<br />Treatment should be symptomatic and supportive. Serum electrolyte levels (particularly potassium)<br />and blood pH levels should be monitored. Studies have shown that timolol does not dialyse readily.</p>
            </div>
        </div>
    </div>

    <div class="col-xs-12">
        <label style="float: left">5. PHARMACOLOGICAL PROPERTIES</label>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="PharmacodynamicProperties">5.1. Pharmacodynamic Properties</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>Pharmacotherapeutic group: Antiglaucoma preparations and miotics, Beta blocking agents, Timolol,<br />combinations, ATC code: S01ED51<br />Mechanism of Action<br />Dorzolamide / Timolol is comprised of two components: dorzolamide hydrochloride and timolol<br />maleate. Each of these two components decreases elevated intraocular pressure by reducing aqueous<br />humor secretion, but does so by a different mechanism of action.<br />Dorzolamide hydrochloride is a potent inhibitor of human carbonic anhydrase II. Inhibition of<br />carbonic anhydrase in the ciliary processes of the eye decreases aqueous humor secretion, presumably<br />by slowing the formation of bicarbonate ions with subsequent reduction in sodium and fluid transport.<br />Timolol maleate is a non-selective beta-adrenergic receptor blocking agent. The precise mechanism of<br />action of timolol maleate in lowering intraocular pressure is not clearly established at this time,<br />although a fluorescein study and tonography studies indicate that the predominant action may be<br />related to reduced aqueous formation. However, in some studies a slight increase in outflow facility<br />was also observed. The combined effect of these two agents results in additional intraocular pressure<br />(IOP) reduction compared to either component administered alone.<br />Following topical administration, Dorzolamide / Timolol reduces elevated intraocular pressure,<br />whether or not associated with glaucoma. Elevated intraocular pressure is a major risk factor in the<br />pathogenesis of optic nerve damage and glaucomatous visual field loss. Dorzolamide / Timolol<br />reduces intra-ocular pressure without the common side effects of miotics such as night blindness,<br />accommodative spasm and pupillary constriction.<br />Pharmacodynamic effects<br />Clinical effects:<br />Clinical studies of up to 15 months duration were conducted to compare the IOP-lowering effect of<br />dorzolamide timolol eye drops solution b.i.d. (dosed morning and bedtime) to individually- and<br />concomitantly-administered 0.5% timolol and 2.0% dorzolamide in patients with glaucoma or ocular<br />hypertension for whom concomitant therapy was considered appropriate in the trials. This included<br />both untreated patients and patients inadequately controlled with timolol monotherapy. The majority&nbsp;of patients were treated with topical beta-blocker monotherapy prior to study enrollment. In an<br />analysis of the combined studies, the IOP-lowering effect of Dorzolamide timolol eye drops solution<br />b.i.d. was greater than that of monotherapy with either 2% dorzolamide t.i.d. or 0.5% timolol b.i.d.<br />The IOP-lowering effect of Dorzolamide timolol eye drops solution b.i.d. was equivalent to that of<br />concomitant therapy with dorzolamide b.i.d. and timolol b.i.d. The IOP-lowering effect of<br />dorzolamide timolol eye drops solution b.i.d. was demonstrated when measured at various time points<br />throughout the day and this effect was maintained during long-term administration.<br />Paediatric population<br />A 3 month controlled study, with the primary objective of documenting the safety of 2% dorzolamide<br />hydrochloride ophthalmic solution in children under the age of 6 years has been conducted. In this<br />study, 30 patients under 6 and greater than or equal to 2 years of age whose IOP was not adequately<br />controlled with monotherapy by dorzolamide or timolol received Dorzolamide timolol eye drops<br />solution in an open label phase. Efficacy in those patients has not been established. In this small group<br />of patients, twice daily administration of Dorzolamide timolol eye drops solution was generally well<br />tolerated with 19 patients completing the treatment period and 11 patients discontinuing for surgery, a<br />change in medication, or other reasons.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
                <label style="float: left" for="PharmacokineticProperties">5.2. Pharmacokinetic Properties</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>Dorzolamide hydrochloride:<br />Unlike oral carbonic anhydrase inhibitors, topical administration of dorzolamide hydrochloride allows<br />for the active substance to exert its effects directly in the eye at substantially lower doses and<br />therefore with less systemic exposure. In clinical trials, this resulted in a reduction in IOP without the<br />acid-base disturbances or alterations in electrolytes characteristic of oral carbonic anhydrase<br />inhibitors.<br />When topically applied, dorzolamide reaches the systemic circulation. To assess the potential for<br />systemic carbonic anhydrase inhibition following topical administration, active substance and<br />metabolite concentrations in red blood cells (RBCs) and plasma and carbonic anhydrase inhibition in<br />RBCs were measured. Dorzolamide accumulates in RBCs during chronic dosing as a result of<br />selective binding to CAII while extremely low concentrations of free active substance in plasma are&nbsp;maintained. The parent active substance forms a single N-desethyl metabolite that inhibits CA-II less<br />potently than the parent active substance but also inhibits a less active isoenzyme (CA-I). The<br />metabolite also accumulates in RBCs where it binds primarily to CA-I. Dorzolamide binds<br />moderately to plasma proteins (approximately 33%).<br />Dorzolamide is primarily excreted unchanged in the urine; the metabolite is also excreted in urine.<br />After dosing ends, dorzolamide washes out of RBCs non-linearly, resulting in a rapid decline of<br />active substance concentration initially, followed by a slower elimination phase with a half-life of<br />about four months.<br />When dorzolamide was given orally to simulate the maximum systemic exposure after long term<br />topical ocular administration, steady state was reached within 13 weeks. At steady state, there was<br />virtually no free active substance or metabolite in plasma; CA inhibition in RBCs was less than that<br />anticipated to be necessary for a pharmacological effect on renal function or respiration. Similar<br />pharmacokinetic results were observed after chronic, topical administration of dorzolamide<br />hydrochloride. However, some elderly patients with renal impairment (estimated CrCl 30-60 ml/min) had higher metabolite concentrations in RBCs, but no meaningful differences in carbonic anhydrase&nbsp;inhibition and no clinically significant systemic side effects were directly attributable to this finding.<br />Timolol maleate:<br />In a study of plasma active substance concentration in six subjects, the systemic exposure to timolol&nbsp;was determined following twice daily topical administration of timolol maleate ophthalmic solution&nbsp;0.5%. The mean peak plasma concentration following morning dosing was 0.46 ng/ml and following&nbsp;afternoon dosing was 0.35 ng/ml.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="PreclinicalSafetyData">5.3 Preclinical Safety Data</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>The ocular and systemic safety profile of the individual components is well established.<br />Dorzolamide<br />In rabbits given maternotoxic doses of dorzolamide associated with metabolic acidosis, malformations of the vertebral bodies were observed.</p><p>Timolol<br />Animal studies have not shown teratogenic effect.<br />Furthermore, no adverse ocular effects were seen in animals treated topically with dorzolamide&nbsp;hydrochloride and timolol maleate ophthalmic solution or with concomitantly-administered dorzolamide hydrochloride and timolol maleate. In vitro and in vivo studies with each of the components did not reveal a mutagenic potential. Therefore, no significant risk for human safety is expected with therapeutic doses of Dorzolamide / Timolol.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-12">
        <label style="float: left">6. PHARMACEUTICAL PARTICULARS</label>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="ExcipientsList">6.1 Excipients List</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>Sodium Citrate<br />&bull; Mannitol<br />&bull; Hydroxyethylcellulose<br />&bull; Hydrochloric Acid 1N and/or Sodium Hydroxide 1N (to adjust pH)<br />&bull; Water for Injection</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="Incompatibilities">6.2. Incompatibilities</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>Not applicable.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="ShelfLife">6.3. Shelf Life</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                24 Months
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="PrecautionsStorageConditions">6.4. Special precautions for storage</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>Do not store above 30&deg;C.<br />Do not use more than 30 days after opening the Alu-Alu pouch.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="ContainerContents">6.5. Nature and contents of container</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>LDPE minims<br />Pack sizes: Alu-Alu covered pouches.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="SpecialPrecautionsDisposal">6.6. Special precautions for disposal and other handling</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>Any unused product should be disposed of in accordance with local requirements.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-12">
        <div class="clearfix">
            <label style="float: left" for="AuthorizationMarketingHolder">7. MARKETING AUTHORISATION HOLDER</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                Jamjoom Pharmaceuticals Factory Company
Plot No. ME1:3, Phase V, Industrial City, P.O. Box 6267, Jeddah-21442,
Kingdom of Saudi Arabia.
            </div>
        </div>
    </div>
    <div class="col-xs-12">
        <div class="clearfix">
            <label style="float: left" for="RevisionDateText">8. DATE OF REVISION OF THE TEXT</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                Oct 2024
            </div>
        </div>
    </div>
</div>

            }    </div>
    <div id="f-div" class="box-data">
        
<div class="row clearfix rtl">
    <div class="container-fluid">
        <!-- Basic Example -->
        <div class="col-lg-6 col-md-6 col-sm-6 col-xs-6">
            <div class="header">
                <h2>صورة المنتج على الرف</h2>
            </div>
            <div class="body">
                <div id="carousel-example-generic" class="carousel slide" data-ride="carousel">
                    <!-- Indicators -->
                    <ol class="carousel-indicators">
                        <li data-target="#carousel-example-generic" data-slide-to="0" class="active"></li>
                        <li data-target="#carousel-example-generic" data-slide-to="1" class=""></li>
                        <li data-target="#carousel-example-generic" data-slide-to="2" class=""></li>
                    </ol>
                    <!-- Wrapper for slides -->
                    <div class="carousel-inner" role="listbox">
                        <div class="item active">
                            
                                <img src="/images/nodrugimags.png">
                        </div>

                    </div>

                    <!-- Controls -->
                    <a class="left carousel-control" href="#carousel-example-generic" role="button" data-slide="prev">
                        <span class="glyphicon glyphicon-chevron-right" aria-hidden="true"></span>
                        <span class="sr-only">Previous</span>
                    </a>
                    <a class="right carousel-control" href="#carousel-example-generic" role="button" data-slide="next">
                        <span class="glyphicon glyphicon-chevron-left" aria-hidden="true"></span>
                        <span class="sr-only">Next</span>
                    </a>
                </div>
            </div>
        </div>
        <!-- #END# Basic Example -->
        <!-- With Captions -->
        <div class="col-lg-6 col-md-6 col-sm-6 col-xs-6">
            <div class="header">
                <h2>الصورة الاساسية</h2>
            </div>
            <div class="body">
                <div id="carousel-example-generic_2" class="carousel slide" data-ride="carousel">
                    <!-- Indicators -->
                    <ol class="carousel-indicators">
                        <li data-target="#carousel-example-generic_2" data-slide-to="0" class=""></li>
                        <li data-target="#carousel-example-generic_2" data-slide-to="1" class="active"></li>
                        <li data-target="#carousel-example-generic_2" data-slide-to="2"></li>
                    </ol>
                    <!-- Wrapper for slides -->
                    <div class="carousel-inner" role="listbox">
                        <div class="item active">
                                <img src="/images/nodrugimags.png">
                        </div>
                    </div>
                    <!-- Controls -->
                    <a class="left carousel-control" href="#carousel-example-generic_2" role="button" data-slide="prev">
                        <span class="glyphicon glyphicon-chevron-right" aria-hidden="true"></span>
                        <span class="sr-only">Previous</span>
                    </a>
                    <a class="right carousel-control" href="#carousel-example-generic_2" role="button" data-slide="next">
                        <span class="glyphicon glyphicon-chevron-left" aria-hidden="true"></span>
                        <span class="sr-only">Next</span>
                    </a>
                </div>
            </div>
        </div>
        <!-- #END# With Captions -->
    </div>
</div>


    </div>

    <!-- #END# Tabs With Custom Animations -->
</div>
        <a style="background-image: url('../images/banner.png');"
           class="scroll-top">
            <img style="margin: 15px;" src="/images/icons/up-arrow2.png" width="35">
        </a>

        <div class="footer navbar-fixed-bottom">
            <small style="color: white; margin-left: 30px;">All Rights Reserved - SFDA &copy; 2020</small>
            <br class="visible-xs visible-sm"><br class="visible-xs visible-sm">

        </div>
    </section>


    <script src="/lib/json2/json2.js?v=w3DjWhUtDqy3bSJKv285C-2kagUtW9F64T9z3xRah8g"></script>
    <script src="/lib/jquery/dist/jquery.js?v=w4hyv6-vmv08RC2hK00wXgxDziKII9paMAbU_M-5dgY"></script>
    <script src="/lib/bootstrap/dist/js/bootstrap.js?v=T574NvJTWc-Pan8hAmnXXc0eZFiqKRp7xQ3sz5QiFOk"></script>
    <script src="/lib/moment/min/moment-with-locales.js?v=5f0RFtuChrGi6osDzegxXWf5yOkmx45i7J9fM1p6P5w"></script>
    <script src="/lib/jquery-validation/dist/jquery.validate.js?v=ZDzsHzuLAtqQVxXwbgRtfAPXQ7UAoJRXBAUDvc9G9CI"></script>
    <script src="/lib/blockUI/jquery.blockUI.js?v=KKcUNqwNyTLaXzvuMyFk6JisiQq6Hk7ZtrciXnEf3Z0"></script>
    <script src="/lib/toastr/toastr.js?v=s1ewxfN8Vn23TAVRLUk8XiQUAw6uWhhuPO9dmtYzUiA"></script>
    <script src="/lib/sweetalert/dist/sweetalert.min.js?v=aPktydUv1rN3mouQeXoKi3ioFTIQlULuqYeoTAA2ihY"></script>
    <script src="/lib/spin.js/spin.js?v=b1plKpQIB-XuGyjWec42MhmhpPzEPzFI3OC8Ia0XIoc"></script>
    <script src="/lib/spin.js/jquery.spin.js?v=i7H7HL08ldqUANgfQInE7LlU2uWUdQMCJ-Q7-_zLutY"></script>
    <script src="/lib/bootstrap-select/dist/js/bootstrap-select.js?v=tXulJKckrq2j2wo8a9hvmXLDEQwhGviPTIYmEzy1dNI"></script>
    <script src="/lib/jquery-slimscroll/jquery.slimscroll.js?v=ESVSX4dkOxamaRoYfcqPM2FfErhgfxS60fp1Fa8ou1w"></script>
    <script src="/lib/Waves/dist/waves.js?v=ZOMv1vwqpT_ezNZGhvr9jJTr_jqu3lYHB7vmpxD7HmA"></script>
    <script src="/lib/push.js/push.js?v=w347yqiscLjM_TxUKpqeUA1LDR3w5vshQpxpTsgkLhE"></script>
    <script src="/lib/abp-web-resources/Abp/Framework/scripts/abp.js?v=EjNSmvtPSqCVK_xG_aTvOp8hmVM_7vwyd3hg45CAMGk"></script>
    <script src="/lib/abp-web-resources/Abp/Framework/scripts/libs/abp.jquery.js?v=XEXcdRYb4eN3XoQCbnM-BSR6UifHRLsXYDIVFZ7Oc6Q"></script>
    <script src="/lib/abp-web-resources/Abp/Framework/scripts/libs/abp.toastr.js?v=h3viOCmHM1K7HnYUuJPDvLchk2Ge8CoKvl6ZJfICgII"></script>
    <script src="/lib/abp-web-resources/Abp/Framework/scripts/libs/abp.blockUI.js?v=vMuHbqHh635SKL2RG2qsGGCDyHg1yFeGqhPKpS34g4k"></script>
    <script src="/lib/abp-web-resources/Abp/Framework/scripts/libs/abp.spin.js?v=djoKib6ssm5DDzbXLe5pD7ayfFg3siaoEk-BFYzQlvI"></script>
    <script src="/lib/abp-web-resources/Abp/Framework/scripts/libs/abp.sweet-alert.js?v=fPp3O_ILaqD0UHiR721w1i4iBtxo3NH7yfldI5dg0_I"></script>
    <script src="/js/admin.js?v=nakObLuf3yPs2VlWrIris5w-48c36X3YIRrxIis7IKQ"></script>
    <script src="/js/main.js?v=x_HDlXByl0okIi4i04d4Q_fNr85GPQi1W8gjs82s-n8"></script>
    <script src="/view-resources/Views/Shared/_Layout.js?v=36YkLzPJaGejZMB10f2T6f1rMVIzDKq96kjfcnxcLVg"></script>


        <script src="/lib/jquery-validation/src/localization/messages_ar.js?v=6kzy-p-PtvkHPWdHWyjMOIfwhBFlUYYv9jnF7zJnpUI"></script>

    <!-- Dynamic scripts of ABP system (They are created on runtime and can not be bundled) -->
    <script src="/AbpServiceProxies/GetAll?v=638865394571695575" type="text/javascript"></script>
    <script src="/AbpScripts/GetScripts?v=638865394571695575" type="text/javascript"></script>
    <script src="/lib/signalr-client/signalr.min.js?v=1yGr-J4NjYMQVt6LP6vocjHIWhO-BFQLfdCs8x1Mv-U"></script>
    <script src="/lib/abp-web-resources/Abp/Framework/scripts/libs/abp.signalr-client.js?v=jTdZBAadu6DXq0iDTFX6vsn4q6bFhKm3XfN8Jz6dSmg"></script>
    
    <!-- View specific scripts -->
    
    <script src="/view-resources/Views/Home/Index.js?v=mAIakROmG_IlahImCtfrMSdaLPTG5Uoh6Z0hM1g3cxw"></script>
    <script src="/view-resources/Views/Home/Result.js?v=0pEgOuTQc8ZyJaaOpJCG7ytkKSCkzEMYCHEJfKDWu4k"></script>
    <script src="/view-resources/Views/Home/DrugsSearch.js?v=04aRniTG_ClH5tABzf7EDwQgWVpkDNpjeJUDSGvOK_Y"></script>

</body>
</html>